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II 
PROJECT AIMS 
Dendritic cells ( DC, an antigen presenting cell-APC) have been shown to 
be present in some tumours, and evidence indicates that these may be an 
indication to the ability of these tumours to provoke an immune response. This 
project investigated the effect of autologous tumour vaccine on benzo-a-pyrene-
induced squamous cell carcinoma in mice, a tumour which is characterised by 
high density of DC within the tumour tissue. The aims of this thesis is to 
determine if tumours with high level of DC infiltration tend to respond to vaccine 
induced immunity, and to examine if DC can be used as a marker to reflect 
tumour response to vaccination correlating with appearance of tumour necrosis 
and appearance of non-DC leukocytes infiltration. 
III 
SUMMARY 
Many studies have correlated the presence of infiltrating immune cells 
within solid tumours, with a more favourable prognosis. These observations 
indicate that the immune system may act to defend against tumour formation or 
growth. The generation of an immune response requires that the tumour cells 
express antigens recognised by the host immune system. The association between 
an impaired immune system with advanced tumours and poor prognosis suggests 
that appropriate stimulation of the immune system against tumour tissues might 
be beneficial. 
Active specific immunotherapy with autologous tumour cells or extract 
has been shown to be effective in causing regression of tumour. The prerequisite 
for effective immunotherapy is the expression of structures on tumour cells 
which are antigenic to the immune system and may function as rejection antigens. 
Various attempts have been made to identify such antigens in different tumours. 
Many antigens have been detected in different tumours, some of these antigens 
are immunogenic and some are not. 
In an attempt to overcoming the difficulty in identifying the tumour 
antigens and in determining which are immunogenic, could be used as an 
indicator of the immunogenicity of tumour cells. DC are an antigen presenting 
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cells, the presence of these cells in the region of tumour tissues may indicate the 
presence of an immunogenic antigens on tumour cells. In this study, squamous 
tumours induced by BP were chosen for immunotherapy by autologous tumour 
vaccine because these tumours were reported to have high numbers of dendritic. 
The application of tumour vaccine to mice possessing these tumours was shown 
to be effective and to lead to an enhanced immune response against tumour cells 
compared to controls. DC infiltration of tumours in test group was significantly 
higher than DC infiltration of control group, this correlating with high degree of 
tumour necrosis and infiltration of tumours by non-DC leukocytes in test group 
compared to the control group. 
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CHAPTER 1 
LITERATURE REVIEW 
1. 1. Historical Background 
A role of the immune system in host resistance against cancer was 
suggested late last century following the recognition of immunity to bacterial 
infection. The concept of treating cancer with tumour cell vaccines and sera arose 
in Germany in 1880 after successful immunization against infectious diseases 
(Currie 1972). At the turn of this century many attempts at using tumour cells as 
a vaccine to treat patients with advanced malignant disease were described, the 
following being typical examples. In 1902 Leyden et al used autologous tumour 
vaccine to immunize patients with advanced cancer, and slight but not significant 
improvement was claimed for some patients. Coca et al (1909) reported 
"softening and disappearance" of tumour masses in three patients following 
administration of tumour cell vaccine. In 1909 Dungern et al injected patients 
with their own tumour cells. The appearance of oedema and redness at the 
injection site were attributed to a specific reaction against tumour cells. Following 
these encouraging results Coca et al (1912) studied a large number of patients 
with advanced tumours who had been treated with autologous or allogeneic 
tumour cells. However the authors stated that, according to the results "active 
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immunization against malignant tumours in human beings is impracticable". 
Some studies reported negative results following immunization with either 
autologous or allogeneic vaccine (Risley eta! 1911; Pinkuss eta! 1913). 
Treatment of cancer by passive immunotherapy was attempted using sera 
from animals immunized by tumour cells. The results were "promising" with 
clinical improvement of the patients being reported in some of these studies 
(Vaughan 1914; Berkeley 1914). Kellock et al (1922) was the first to use X-rays 
to irradiate tumour cells before vaccination. This aimed to reduce the risk of 
tumour implantation whilst retaining the immunizing value of the cell. However, 
in this trial no therapeutic effect could be demonstrated. Tissue extract was also 
used as a vaccine following extensive degradation of tumour cells (Rubens-Duval 
1932). Frozen autologous tumour tissues were used to immunize cancer patients 
by subcutaneous implantation (Stone et al 1955). In an attempt to enhance the 
immunogenicity of tumour cells autologous vaccine mixed with adjuvant or 
antigenic proteins was used in some trials (Graham eta! 1959,1962; Czajkowski 
eta! 1966, 1967; Cunningham eta! 1969). 
1. 2. Immunosurveillance 
The "immunosurveillance" theory was advanced by Burnet in 1970. He 
proposed that one of the important functions of the immune system in mammals 
was the detection of non-self antigen, a function he attributed mainly to thymus- 
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dependent lymphocytes. The role of thymus-dependent lymphocytes in 
immunosurveillance was based on a study that showed that thymectomized 
animals were unable to reject transplanted tumours. However providing these 
animals with lymphocytes from normal donors led to elimination of these tumours 
(Law 1969). Further evidence appeared to be the observation that mice infected 
with an oncogenic virus were susceptible to cancer development if these animals 
were pre-treated with anti-lymphocyte serum (Hirsch et al 1968). 
Moller (1975) and Schwartz (1975) have discussed the controversy over 
immunosurveillance. Criticism of this theory arose from the fact that the increased 
incidence of tumours in thymectomized animals in the previous studies had no 
relationship to spontaneous development of tumours. In a study of 11,000 nude 
mice over 4 months none of the mice developed spontaneous tumours (Rygaard et 
al 1974). One year later another study criticized this finding, because many 
spontaneous tumours developed in nude mice over two years, the average age of 
tumour development being around 14 months (Outzen et al 1975). 
Penn (1976) recorded that the incidence of malignant neoplasms in 
immunocompromised patients was 5-6%, 100 times greater than that in the 
general population. A high proportion of these tumours were of lymphoid origin. 
However according to the immunosurveillance concept a wide variety of tumour 
types should arise. The incidence of the most common tumour in women (breast 
cancer) does not increase significantly in immunocompromised patients 
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(Schwartz 1975; Moller eta! 1975). Blohme et al (1984) in their study of renal 
transplant patients receiving immunosuppression therapy, reported that malignant 
and pre-malignant skin lesions increased 3-fold in transplanted patients compared 
to the control population. Several immune mechanisms have been suggested as 
, playing a role in proposed immunosurveillance. Ioachim (1976) demonstrated 
lymphocyte infiltration at the tumour site and suggested a role for antibodies 
because of identification of plasma cells in the infiltrate. The role of T cells in 
immunosurveillance was supported by Antonia eta! (1996) following the finding 
that malignant transformed cells express T-cell co-stimulatory molecule B7-1 
which activates T cells after encountering a tumour cell. In an animal model it 
was demonstrated that T-cells mediated immunosurveillance in an MHC-
dependent manner (Yamasaki et al 1996; Trivedi eta! 1997). 
Baldwin (1977) attributed immunosurveillance to NK cells since NK cells 
from normal individuals were found to be cytotoxic to tumour cells and more 
cytotoxic than NK cells taken from individuals with cancer. The ability of these 
cells to lyse target cells in non-MHC-restricted manner and without previous 
sensitization strongly suggested this cell as a likely candidate for an 
immunosurveillance function (Cristoforoni et al 1994). Depletion of NK cells in 
mice led to significantly increased growth of transplanted tumours. This was 
taken to indicate that these cells were involved in an immunosurveillance 
mechanism" (Martiniello et al 1996). Renneboog et al (1996) reported a case of 
spontaneous disappearance of a neoplastic clone following the withdrawal of 
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Azathioprine (an immune-suppressive agent), the remission in this case was 
attributed to the recovery of immunosurveillance. MHC antigen may play an 
important role in immunosurveillance, down-regulation of this antigen on tumour 
cells being associated with development and invasion of tumours (Garrido et al 
1997; Vora et al 1997). Recently Dudley et al (1996) reported that the incidence 
of gastrointestinal polyps did not change in severely immunodeficient mice. The 
absence of immunosurveillance might be due to the lack of immunogenicity in the 
polyps. These studies suggest a role for cell-mediated immunity in tumour 
rejection. 
1. 3. Evidence of Immunological Reaction to Tumour Cells 
Tumour infiltration by lymphocytes, macrophages and plasma cells occurs 
in both animal and human tumours. Handley (1907a) was among the first to 
correlate the regression of tumours with inflammatory response in patients with 
malignant melanoma. Moreover, Handley referred to "body resistance" to tumour 
cells in the early stages of the disease (Handley 1907 b). 
Many studies since then have suggested that infiltration of tumours by 
leukocytes is associated with better prognoses and tendency to spontaneous 
regression. Black eta! (1953,1958) showed that in patients with breast cancer the 
presence of sinus histiocytosis (distension of the lymph node sinusoid by large 
cells of mononuclear phagocytic type) in the regional lymph nodes of blimary 
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cancers is associated with a better prognosis. Tumours with marked sinus 
histiocytosis are associated with a lower incidence of metastases (Anastassiades et 
al 1959). Takraklides et al (1974) showed that high T-cell:B-cell ratio is 
associated with a better prognosis. A well documented case of long-term 
spontaneous regression of malignant melanoma with evidence of host immune 
resistance was reported by Bulkley (1975). Histological examination of the 
lesions revealed lymphocyte infiltration and tumour necrosis. Analysis of TIL 
isolated from regressive melanoma revealed in situ clonal expansion which 
strongly suggested that antigen driven selection underlay the clonal expansion at 
the tumour site (Ferradini et al 1993; Sensi et al 1997). TIL display MHC-
restricted cytotoxic activity against autologous tumour cells in vitro and most 
probably contribute to tumour regression (Mackensen et al 1994, 1997). Several 
TSA which are recognised by autologous TIL have been reported and the genes 
coding for these antigens have been identified (Coulie et al 1994; Mori et al 
1996; Wagner et al 1997; Durrant et al 1997). 
1.4. Tumour Antigen 
Tumour specific antigen (TSA) is a constituent of tumour cells that is 
capable of evoking an immune response specifically to the tumour cells. Most 
candidate TSA have eventually been found on other non-malignant tissues. For 
example, certain gangliosides have been detected on melanoma, but have also 
been shown on the cell membrane of other tissues, especially brain (Pukel 1982). 
Antibodies against these antigens are detected in serum from cancer patients and 
at very low levels in normal individuals (Watanabe et al 1982). 
Many abnormal proteins are produced by tumour cells that cannot be 
recognised by the immune system. Normally occurring proteins may be produced 
in abnormally high amounts by some tumours. TSA can be used as a tumour 
marker (Chabanas et al 1997), the presence of tumour markers may be detected 
prior to clinical detection of the primary lesion so that screening for these may 
lead to early tumour detection and treatment with better prognosis. The level of 
such antigens may be correlated with the prognosis (Goldman et al 1993; 
Yamazaki et al 1993). Such markers may be also used as an indication of 
response to treatment (Carrel et al 1973), development of recurrence (Rose et al 
1993) or as an indication of the activity of the disease (Dreyfuss et al 1992; Segal 
et al 1997; Moretti et al 1997). Furthermore, down-regulation or up-regulation of 
certain antigens might correlate with transformation of normal cells to tumour 
cells (Nollau et al 1997). 
1.4. I. Types of Tumour Antigens 
I. Differentiation Antigens 
Differentiation antigens are found in normal cells that have a common 
foetal origin or in cells during a particular phase of their differentiation, { for 
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example the surface antigens found on T-cells and their precursors during 
differentiation from stem cell to mature cell (Foon et al 1982)), or on dividing 
cells but not on resting cells, { for example receptors for interleukin-2 (Uchiyama 
et al 1981)). Most of the antigens that have been identified on malignant cells are 
found on normal cells during differentiation or on tissue of the same origin. Some 
melanoma antigens which are differentiation antigens can be detected on foetal or 
adult melanocytes (Houghton eta! 1982). Daar (1981) showed that the presence 
of differentiation antigen on breast tumour cells reflects the degree of tumour cell 
differentiation. Some tumour cells express differentiation antigens which are not 
found in the tissue of origin but on another type of tissue (Daar et al 1982). 
Oncofoetal Antigens 
Oncofoetal antigens are normally found in normal foetal tissues but in 
only small amounts in adult tissues. These antigens can also be found in small 
amounts in benign tumours or in the sera of normal subjects (Moore et al 1971; 
Chu eta! 1972; Roushlahti et al 1972; Reithdorf et al 1997). 
Carcinoembryonic antigen (CEA) was first demonstrated in rabbits 
immunised with human colonic cancer. The rabbits developed antibodies that 
reacted with foetal-type colonic mucosa but not with normal mucosa (Gold et al 
1964). Using sensitive assays Chu et al (1972) reported that small amounts of this 
antigen were detected in normal serum. Elevated serum levels of this antigen are 
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found in patients with other varieties of carcinoma and in patients with non-
neoplastic diseases (Moore et al 1971). 
III. Chemically Induced Tumour Antigens 
Abelev et al (1963) found that chemically induced hepatoma in mice 
synthetised protein similar to alpha-globulin found in the sera of foetal and 
neonate mice but not in adult mice. The characteristic feature of chemically 
induced tumours is the diversity of antigenicity (Klein et al 1960). Diversity of 
the antigenicity could also be recognised within primary tumours induced by the 
same carcinogen in the same individual (Globerson et al 1964). The incidence 
and antigenicity of carcinogen-induced tumour relates directly to the 
concentration of the carcinogen and the frequency of exposure (Prehn et al 1975). 
Chemical carcinogen may affect the expression of tumour cell protein. 
Carcinogen reduces some surface proteins, while other proteins show higher 
expression when compared to normal cells. Some proteins had been detected only 
in the treated cells but not in normal cells. These new proteins may act as TSA 
(Altevogt et al 1985). 
IV. Virus-Induced Tumour Antigens 
It has been shown in experimental animals that DNA viruses have 
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oncogenic potential. Some of these viruses had been suggested as a causative 
agent of certain human neoplasms, for example the association between EBV and 
Burkitt's lymphoma (Klein et al 1975), and herpes simplex human papilloma 
viruses and cervical carcinoma (Smith et al 1979; Yamada et al 1997). In a 
virally transformed cell, viral gene can be incorporated into the DNA of the 
transformed cells and then translated by the cell ribosome into protein which can 
incorporate into the cell membrane of infected cells. This protein could act as a 
TSA and become a target for T-cells (Svedmyr et al 1975; Iezzi et al 1997). A 
significant feature of virus-induced tumours is that tumours induced by the same 
virus have common antigens. These antigens can induce rejection of the 
transplanted tumour in syngeneic hosts immunised against the inducing virus 
(Sjogren et al 1961). The similarity of tumour antigen induced by the same virus 
occurs regardless of the morphology of the tumour and the species of the animal 
model (Klein 1968, Levitskaya et al 1995). 
V. Major Histocompatibility Complex Antigens (MHC) 
Doherty et al (1975) were among the first to refer to MHC and its role in 
cell mediated immunity. This antigen in humans is represented by human 
leukocyte antigen (HLA). Class I 1-ILA is found on most nucleated cells (Daar et 
al 1984a). Class II HLA was thought to be present on cells only related to the 
immune system, however this antigen was also detected in non-lymphoid 
epithelial tissues (Daar et al 1984b). The expression of MHC antigen on tumour 
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cells varies. Some tumour cells lose MHC antigen expression which is found in 
the tissue of tumour origin (Carrido et al 1976). Other tumours may express new 
MHC antigen which is found usually on other types of tissues (Wilson et al 
1979). Some murine tumours express MHC antigen which is normally found in 
other species (Parmiani 1980). The expression of this antigen on tumour cells 
was found to play an important role in development of tumour immunity (Fossati 
eta! 1984; Guo et al 1997; Chang eta! 1997, Yang et al 1997b). 
The importance of MHC antigen in tumour immunity comes from the 
relationship of cytotoxic T-cell activity and the expression of this antigen on 
tumour cells. The reactivity of cytotoxic cells is restricted by an antigen encoded 
in the genes of class I MHC antigen (Zinkernagel et al 1979; Mackensen et al 
1997). Moreover, effective resistance against tumour cells by T cell mediated 
cytolysis cannot be achieved if the tumour cells have lost MHC antigen (Tursz et 
al 1977; Guo et al 1997). Virus may modulate the expression of class I antigen 
on the infected cells. In EBV-carrying Burkitt's lymphoma the expression of such 
antigen is reduced, which may contribute to the resistance of these cells to 
cytotoxic T-cells. Expression of MHC antigen in EBV-infected lymphoblastic cell 
lines make these cells more susceptible to effector cells (Jilg 1991). 
The degree of MHC expression might reflect the tumourigenicity and 
metastatic potential of malignant cells, since the metastatic potential is increased 
if the expression of MHC is reduced on the surface of the malignant cell (Kane et 
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al 1986; Abdel-Wahab et al 1997; Conway et al 1997). Down-regulation of 
MHC in tumour cells correlates with disseminated disease and could be a 
mechanism by which tumour cells escape immunosurveillance (Van Driel et al 
1996). The correlation of the magnitude of expression of MHC antigen and the 
differentiation of the tumour cells has been investigated. Poorly differentiated 
tumour cells are associated with reduced density of MHC antigen whilst in well 
differentiated tumour cells the expression of MHC antigen is normal (Tomita et al 
1990; Esteban et al 1990; Conway et al 1997). 
This observation extends to include the importance of this antigen in 
recognition of TSA, since a strong relationship was detected between the 
immunogenicity of tumour cells and the expression of MHC antigen (Baetselier 
et al 1980; Abdel-Wahab et al 1997). CTL recognise TSA in association with 
MHC antigen and the cytotoxic effect of CTL against tumour cells is determined 
by the presence of specific MHC antigen (Traversari et al 1992; Coulie et al 
1994; Peiper 1997; Yang et al 1997b; Chang et al 1997). It has been shown that 
the role of CTL in immunosurveillance is an MHC antigen-dependent 
mechanism since MHC antigen-positive tumour cells are rejected by CTL while 
MHC antigen-negative tumour cells can grow progressively in the brain 
(Yamasaki et al 1996; Vora et al 1997). 
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1. 5. Cells Involved in Immune Response against Tumour 
Many reports have appeared describing cellular immune responses against 
cancer. Early studies indicated that this anti-tumour activity is specific (Currie et 
al 1972; Akiyama et al 1983). However immune cells can kill tumour cells in a 
non-specific manner (Mantovani et al 1979). Infiltration of tumour tissues by 
immune cells such as macrophages, plasma cells, DC and lymphocytes indicates a 
host anti-tumour response (Elston et al 1973; Si et al 1996; Maehara et al 1997). 
Tumour infiltration by immune cells has been correlated with a favourable 
prognosis (Matsuda et al 1990; Zeid et al 1993; Berd et al 1997). 
1. 5. 1. Lymphocytes in Anti-tumour Immunity 
The anti-tumour effect of lymphocytes is attributed mainly to T cells 
rather than B cells (Pape et al 1977). The recognition of cellular antigen by T 
cells is quite different from the recognition of the antigen by antibodies. T cells 
recognize cellular antigen in association with MHC antigen on the cell surface 
(Zinkernagel et al 1979; Peiper et al 1997; Mackenson et al 1997). Blocking of 
class I HLA by monoclonal antibody prevents the recognition of autologous TSA 
by T-cells (Anichini et al 1985). The recognition of allogeneic tumour cells is not 
prevented by blocking this MHC antigen (De Vries et al 1984; Coulie et al 1994; 
Yamasaki et al 1996). However others have shown that MHC antigen is involved 
in recognition of allogeneic antigen (Yang et al 1997b). 
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The subset of T-cells which has cytotoxic effect is the cytotoxic T-
lymphocyte (CTL). CTL were first recognized to cause lysis of target cells in a 
mixed lymphocyte reaction in vitro (Cerottini et al 1974). Study of T-
lymphocytes (TL) later revealed that these cells can kill tumour cells and virus-
infected autologous cells including oncogenic viruses (Zinkernagel et al 1975; 
Gooding et al 1983; Mukherji et al 1983). 
CTL can be isolated from the peripheral blood lymphocytes (PBL) of 
cancer patients. These cells were found to be cytotoxic to autologous tumour cells 
in vitro after activation and culturing with autologous tumour cells (Anichini et al 
1985; Mukherji et al 1986), allogeneic tumour cells (Zarling et al 1976; Vancy et 
al 1981), mixed leukocyte culture (MLC) (Zarling et al 1979) and EBV 
transformed B cells (De Vries et al 1984). These studies indicate that peripheral 
blood lymphocytes (PBL) contain the precursor cells which are cytotoxic to 
autologous tumour cells. 
CTL can also be isolated from tumour infiltrating lymphocytes (TIL) 
which may be obtained from tumour specimens by mechanical or enzymatic 
treatment. PBL are more cytotoxic against tumour cells than TIL (Mukherji et al 
1986). Some studies have reported that these cells are more cytotoxic than PBL 
when taken from highly antigenic tumour (Brunner et al 1981). Following the 
separation of either PBL or TIL, these cells may be expanded in vitro by 
interleukin-2 (IL-2), while maintaining their cytotoxic function (Mukherji et al 
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1983; Topalian et al 1989). Analysing T cell receptors (TCR) of the lymphocytes 
infiltrating regressive melanoma revealed that there is clonal expansion of TIL 
which display MHC antigen-restricted cytotoxic activity against autologous 
tumour cells and which is associated with tumour regression (Mackensen et al 
1994; Ferradini et al 1993; Chang eta! 1997; Mackenson eta! 1997). 
Some studies have shown that the cytotoxic effect of CTL against tumour 
cells is specific. TIL with specific anti-tumour activity express CD4 and CD8 
markers (De Vries et al 1984; Topalian et al 1989). CD4 antigens play a role in 
CTL antigen recognition (Spits et al 1982). There are two major sub-
populations of T cells: CD8+ (T suppressor/cytotoxic) and CD4+ 
(helper/inducer: Reinherz eta! 1981). These TL derived from peripheral blood or 
infiltrating lymphocytes interact with autologous tumour cells through a T-cell 
receptor (TCR)-dependent mechanism (Maccalli et al 1994; Vondrys et al 1997). 
TL which carry these receptors are responsible for tumour immunity (Mackensen 
et al 1994; Frey et al 1996) 
The immune response mediated by lymphocytes is a result of interaction 
between different sub-populations of T-cells. Although the cytotoxic activity of 
T-cells was thought to be due to of CD8+ CTL, CD4+ CTL are also cytotoxic to 
autologous tumour cells, i.e. CD4+ and CD8+ T-cells are functionally 
heterogeneous, e.g. T-cells within CD8 contain cytotoxic as well as suppressor 
cells and cells within the CD4 sub-population induce suppression or could be 
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cytotoxic (Mukherji et at 1986; Frey et at 1996). 
While some experiments show that generation of CTL is independent of 
T-helper cells (Inaba et al 1987), others indicated the need for T-helper cells in 
CTL generation (Ramarli et at 1984). Apasove eta! (1994) referred to the role of 
CD4+ cells in generation of CTL in MHC I-antigen deficient mice. Treating these 
mice with anti-CD4 monoclonal antibodies led to abrogation of anti-tumour 
response. On the other hand, other experiments have shown that tumour rejection 
is mainly a function of CD8+ but not CD4+ cells (Ramarathinam et at 1994; 
Thai et al 1996; Guo eta! 1997; Yang et al 1997b). 
Activation of T-helper cells and generation of CTL require interaction 
with specific antigen presented in combination with MHC antigen (Topalian et at 
1996; Mackenson et al 1997) as well as other stimulatory signals from antigen 
presenting cells (Schwartz et at 1990; Linsley et al 1997; Boussiotis et at 1997; 
Chaux et at 1997; Brossart et at 1997). Thus if an antigen is presented to CTL 
without the appropriate co-signals CTL may become anergic. It has been found 
that this co-signal is delivered to CTL through the B7 surface molecule, present 
on the surface of dendritic cells (DC), macrophages and activated B and T cells 
and blocking of this interaction leads to inhibition of immune response (Linsley 
et at 1993; Boussiotis et al 1996). Human tumour cells transfected with the B7 
gene may simulate CTL in the absence of T helper cells and accessory cells, 
whilst non-transfected cells fail to produce a response (Dohring et al 1994; 
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Ramarathinam et al 1994). Immunization of mice with tumour cells express the 
B7 molecules led to significant amplification of cytotoxic effect of CD+ TL 
(Johnston et al 1996). 
I. 5. 2. Dendritic Cells in Anti-Tumour Immunity 
Dendritic cells (DC) were described more than a century ago by Paul 
Langerhans in a section of human epidermis. Langerhans thought that this cell 
was related to neural tissues, because it could be stained with gold chloride 
(Langerhans 1868). 
DC in the epidermis are distinguished from other epidermal cells by their 
clear cytoplasm, the convoluted appearance of the nuclear membrane due to the 
presence of deep clefts and their dendritic shape. Electron microscopy shows that 
DC are characterised by the absence of desmosomes and the presence of granules 
which appear as linear structures with rounded ends ("tennis-racquet"), which are 
known now. as Birbeck granules (Birbeck et al 1961). These 'tennis racket'-like 
granules are specific for this cell. In addition, well developed endoplasmic 
reticulum and Golgi complex are characteristic, with many lysosomes present in 
the cytoplasm (Zelickson 1965). 
DC are derived from bone marrow (BM: Frelinger et al 1979, Katz et al 
1979), and may share a common pro-generator with macrophages (Volc-Platzer et 
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al 1984; Austyn et al 1993). These cells spread from BM to lymphoid and most 
non-lymphoid tissues, and a migratory form of these cells is found in peripheral 
blood and afferent lymph (Metllay et al 1989). 
DC are devoid of surface markers which are specific to NK cells, 
macrophages, T-cells and B-cells (Austyn eta! 1987). DC express high quantities 
of class II MHC antigen which is essential for antigen presentation to T cells. In 
animal models it was reported that up-regulation of class II MHC antigen on DC 
occurs following antigen administration. This up-regulation of MHC correlates 
directly with the ability of DC to present an antigen to T cells (Hopkins et al 
1989). The density of DC in tumour tissues correlates directly with the expression 
of class H MHC antigen by tumour cells (Bigotti eta! 1991). 
DC are a heterogeneous group of cells that vary in both phenotype and 
function. The main function of DC is to present foreign antigen in complex with 
MHC to T cells, and to deliver an activating signal to T cells. DC in the thymus 
present self antigen-MHC antigen complex to developing thymocytes to induce 
tolerance to self-peptide (Austyn et al 1987; Metllay et al 1989; Linsley et al 
1997; Boussiotis et al 1997; Chaux eta! 1997; Brossart et al 1997). 
The role of DC in chemically induced cutaneous tumours has been 
investigated in many animal studies. Application of 7,12-dimethyl benzo-a-
anthracene (DMBA) led to a decrease in the number of DC, the density lowest 
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when the tumour was well developed. Cessation of carcinogen application was 
followed by an increase the number of DC to a normal level, which was 
associated with regression of the tumour (Muller et al 1985). These carcinogens 
may prevent the development of any potential immune response against 
transformed cells by affecting the number and the function of DC. This reflects 
the role of DC in anti-tumour immunity. On the other hand, application of benzo-
a-pyrene (BP) was accompanied by increased number of epidermal DC 
(Langerhan's cells, LC). Tumour induced by BP is also characterised by the 
presence of high number of DC (Ruby et al 1989). Tobacco smoke condensate 
(TSC) application is associated with an increased number of DC. However the 
morphology and the function DC were abnormal. Following the development of 
tumours cessation of TSC application was associated with reversible changes of 
DC morphology and function, increased number of DC, regression of tumours 
and tumour necrosis (Zeid et al 1995). Viruses promote the development of 
tumour in the same way as chemical carcinogen i.e. diminished numbers of LC 
leads to decreased local immune-surveillance, and subsequently development of 
the cancer (Younes et al 1968; Caorsi et al 1984; McArdle et al 1986). 
Abnormal distribution and function of DC were also described in spontaneous 
tumours (Gatter et al 1984; Egan et al 1986; Stene et al 1988; Wilson 1991). 
The infiltration of lung tumour with dendritic cells was found in patients 
with adenocarcinoma, squamous cell carcinoma and type II alveolar cell 
carcinoma. The density of DC in well or moderately differentiated carcinoma was 
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higher than those with poorly differentiated tumours (Furukawa et al 1984; 
Nakajima et al 1985). The association of DC with well differentiated 
adenocarcinoma and the better prognosis of these tumours may be due to presence 
of tumour antigen on the differentiated tumour cells attracting DC to the tumour 
site. Some studies have shown that there is a correlation between the histological 
stage of the tumour and the density of DC infiltration (Matsuda et al 1990; 
Maehara et al 1997). 
Clinical studies indicate that the regression or progression of tumours can 
be correlated to the number of DC infiltrating cancer tissues. In general, growing 
tumours are accompanied by decreased density of DC (Furukwa et al 1985; 
Nomori et al 1986; Tsujitani et al 1987; Maehara et al 1997). The prognosis in 
tumour-bearing patients can be correlated with the density of DC in patients with 
colorectal carcinoma, gastric carcinoma, papillary carcinoma of the thyroid and 
oesophageal carcinoma (Schroder et al 1988; Ambe et al 1989; Tsujitani et al 
1990; Matsuda et al 1990). 
DC, as an antigen presenting cell (APC), plays an important role in 
initiating the immune response against specific antigen (Stingle et al 1978, Sertl et 
al 1986; Hopkins et al 1989). DC participate also in the immunity against 
neoplasms by presenting TSA to other immune cells (Grabbe et al 1991, 1992). 
TSA presentation by DC is an important step in initiating an adoptive anti-tumour 
immunity, this immunity is antigen specific and capable of rejecting tumour cells 
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carrying that antigen (Celluzzi et al 1996; Ellem eta! 1997). 
Infiltration of tumour tissues with such cells can serve as an indicator to 
the ability of tumour cells to evoke an immune response (Ambe eta! 1989). This 
ability might be due to the presence of TSA. Recognition of TSA by this cell 
initiates an immune response against tumour cells carrying this antigen, this 
immunity is mediated mainly by CTL (Bakker et al 1995; Zitvogel et al 1996a, 
C; Van-Schooten et al 1997; Mayordomo et al 1997). Correlation was found 
between DC and infiltration of tumour tissues by other immune cells especially 
lymphocytes (Watanabe et al 1983; Drijkoningen et al 1987; Ambe et al 1989; 
Zeid et al 1993). High numbers of DC were found in tumours infiltrated by other 
immune cells. 
I. 5. 3. Natural Killer Cells in Anti-Tumour Immunity 
The cytotoxic effect of natural killer (NK) cells was first recognised 
following the observation that lymphocytes from the thoracic duct of dogs with 
transplanted kidneys were cytotoxic to the donor kidney tissues (Coverts 1960). 
The cytotoxicity of these cells is non-MHC-restricted. NK cells from normal 
subjects also have a cytotoxic effect on tumour cells. This type of cell mediates 
cytotoxicity against tumour cells which is non-adoptive and non-MHC restricted, 
and was named "natural cytotoxicity", and the effector cells mediating this 
activity were termed natural killer cells (NK). Anti-tumour effects are not the only 
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function of NK cells. These cells also play a role in immune regulation, immunity 
against microbial agents such as viruses, and other functions (Trinchieri et al 
1984; Trinchieri 1989; Robertson et at 1990). 
Some authors have suggested that NK cells could be any lymphoid cells 
from non-immunized individuals which mediate non-MHC restricted cytotoxicity 
(Ritz et at 1988). However others have suggested that NK cells represent a new 
subset of leukocyte which may have its own lineage (Lanier et at 1986). NK cell 
maturation occurs in the absence of functional thymus, and functional NK cells 
are found in nude mice and severely immune deficient mice (Dorshkind et at 
1985). 
The cytotoxicity of NK cells can be measured in various ways, the most 
frequent method using K562 target cells. This cell line was derived from a patient 
with chronic myelogenic leukemia in blastic crisis (Lozzio et al 1976). The 
identification of NK cells depends on the ability of these cells to mediate 
spontaneous cytotoxicity. However, this function is shared by other types of cells 
such as macrophages and other T-cells. Thus, other features were considered 
necessary to identify this population of cells, such as cell surface antigen, 
phenotype and morphology (Lanier et at 1986). NK cells were described as 
Large Granular Lymphocytes (LGL) (Timonen et at 1981), however this feature 
may not be exclusive since not all NK cells have this feature. Assuming the 
morphology of NK cells as LGL, 3.6-8% of lymphocytes in peripheral blood 
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were found to belong to this sub population (Trinchieri 1989; Timonen et al 
1981). 
Fc receptors for the Fc portion of IgG are found on most NK cells. These 
receptors are characterized by low affinity to IgG unlike those found on other 
lymphoid cells. The Fc receptors are not important for the function of these cells 
since blocking or modulation of receptors does not affect cell function (Kay et al 
1977; 1979a; 1979b; Eremin et al 1978 ). Fc receptors are involved in the 
regularity mechanism of NK cells (Robinowich et al 1996). 
NK cells have the ability to form rosettes with sheep erythrocytes (Key et 
al 1980). Since rosette formation is a characteristic feature of T cells, NK cells 
were thought to belong to this lineage (Key et al 1977). Unlike T-cells, NK cells 
have low affinity for sheep erythrocytes (West et al 1977). CD4 antigen is not 
found on NK cells, however some NK cells carry CD8 antigen on the cell 
surface, an antigen which is also carried by cytotoxic T-cells (Perussia et al 
1983). NK cells also react with antibodies used as markers for myeloid lineage 
(Key et al 1980). The precise lineage of NK cells remains unknown. Several 
studies have suggested that these cells are derived from CD34 bone marrow 
progenitors (Lotzova et al 1993; Miller et al 1992, 1994). Res et al (1996) 
referred to the role of the thymus in NK cell differentiation. 
The role of NK cells in immune defence against malignancy has been 
23 
shown in animal models and humans. In the murine system it was found that there 
is a direct relationship between the activity of NK cells and the progression of 
primary tumours and metastasis formation (Trinchieri 1989). Many studies have 
shown peripheral blood natural cytotoxicity to be reduced in patients with cancer 
(Tsutsi et al 1992; Le-Fever et al 1991; Lakhadar et al 1989; Cunningham et al 
1981; Hersey et al 1979). Moreover, NK cell activity in patients with cancer 
reflects the subsequent response to chemotherapy (Garzetti et al 1994). 
Many investigators have shown that the cytotoxic effect of NK cells is not 
specific. A wide range of tumour cells are susceptible to NK activity. NK cells 
from homologous species are more effective than that from heterologous species 
(Roozemond et al 1986). Evidence has demonstrated some selectivity in reactivity 
against target cells (Mason et al 1993). The susceptibility of target cells to the 
cytotoxic effect of NK cells seems to depend on the structure of the cell 
membrane, since transfer of liposome containing membrane from sensitive cells 
to insensitive cells makes the later sensitive to NK cytotoxicity (Roozemond et al 
1986). 
Activation of the cytotoxic mechanism on NK cells requires a structure on 
the target cells other than the structure for cell binding to NK cell (Trinchieri 
1989; Trinchieri et al 1981). There is little information about specific receptors 
used by NK cells for recognition and killing of target cells. CD54 molecules on 
the surface of NK cells are important for the cytotoxic effect of these cells against 
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some tumour cell lines (Cristoforoni et al 1994). 
Primitive cells have been shown to be more sensitive to NK cells than 
mature cells. For example NK cells lyse undifferentiated but not differentiated 
embryonic carcinoma cells (Stern et al 1980). Some tumour cell lines which are 
resistant to lysis by polymorphonuclear cells (PMN) and MHC non-restricted T 
cells are sensitive to NK cells. Several studies have suggested the involvement of 
MHC in NK cell-mediated cytotoxicity with inverse correlation described 
between expression of this molecule on the target cell and the susceptibility to 
cytotoxic effect of NK cells (Pointek et al 1985; Jiang et al 1996). Increase in 
the expression of MHC on the target cells by interferon (IFN) leads to decreased 
sensitivity to the action of NK (Cristoforoni et al 1994). NK cells express cell 
surface receptors for MHC. Interaction of these receptors with self MHC leads to 
inhibition of cytolytic activity of NK cells (Andrea et al 1996; Fry et al 1996) 
The activity of NK cells can be modulated by several agents, the most well 
known being IL-2. Culture of NK cells in media containing IL-2 augments the 
activity of these cells against target cells (Lotzova et al 1987). IL-12 was found to 
have a synergistic effect with IL-2 (Rossi et al 1994). Lymphokine activated 
killer cells (LAK) which mediate non-MHC restricted cytotoxicity were reported 
to be NK cells (Trinchieri 1989). 
NK cells may play a major and important role in host immunity against 
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cancer and in immunosurveillance against tumour cells (Yamasaki et al 1996; 
Martiniello et al 1996), since the action of these cells does not require pre-
exposure to target cells. The finding that some tumour-bearing hosts have 
depressed NK cell activity has led to the suggestion that activated NK cells could 
be used in immunotherapy of cancer. 
1. 5. 4. Macrophages in Anti-Tumour Immunity 
Macrophages are a heterogeneous group of cells that participate in many 
aspects of the immune response. These cells are required for development of 
specific immunity mediated by other immune cells. In addition macrophages may 
play a major role in immunity against cancer in general, and against metastatic 
tumours specifically (Evans et al 1972; 1973). 
Tumour infiltration by macrophages may reflect the role of this cell in 
tumour defence, rather than purely ingestion of necrotic materials within tumour 
tissues. This is supported by the fact that macrophages infiltrate necrotic and 
healthy tumours to the same degree (Evans 1972). Moreover, tumour infiltration 
by macrophages correlates with the biological behaviour of tumours, that is, 
macrophage infiltration inhibits tumour growth and tumours heavily infiltrated by 
macrophages are less likely to metastasize (S yenning et al 1979; Eccles et al 
1974). 
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Defective macrophage function has been found in patients with cancer. 
Treatment of these patients surgically or with chemotherapy enhances the 
function of macrophages (Kleinerman et al 1980; Normann et al 1979). The 
ability of tumour cells to metastasize has been correlated to tumour cell sensitivity 
to macrophage effects, i.e. the tumour cells most sensitive to macrophages are the 
least likely to metastasize (Miner et al 1983). 
Macrophages may affect tumour cells by two different mechanisms: 
inhibition of tumour cell proliferation (cytostasis) and tumour cells lysis 
(cytolysis). The cytostatic action of macrophages are not specific to tumour cells, 
since both normal and transformed cells can be affected by this mechanism 
(Keller 1976). The effect of macrophages on cell proliferation is mediated by its 
action on DNA synthesis (Krahenbuhl et al 1977; 1980). 
The lysis of tumour cells by macrophages is mediated by two mechanisms, 
antibody-dependent and antibody-independent. The antibody-independent 
macrophage cytotoxicity was first described by Alexander et al (1971). This 
action of macrophages required contact with the target cells, but the cytotoxicity 
does not involve phagocytosis of the target cells (Hibbs et al 1972; Mantovani et 
al 1977). Following this specific contact, the non-specific reaction takes over, 
whereby macrophages secrete cytolytic factors which mediate the cytotoxic effect 
(Johnson et al 1981). The binding of macrophages to tumour cells is a specific 
process mediated by specific receptors on tumour cells (Marino et at 1981). 
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Antibody-dependent macrophage cytotoxicity is lysis by macrophages of 
target cells which are coated by specific antibodies. The recognition and binding 
of macrophages to the target cells is mediated through Fc receptors on 
macrophages, which bind the Fc portion of immunoglobulin. Different types of 
these receptors have been recognised: FcRI, FcRII and FcRIII (Diamond et al 
1981; Unkeless et al 1981). These receptors have different functions. FcRI and 
FcRII mediate antibody-dependent cellular cytotoxicity, but FcRIII does not play 
a direct role in this mechanism (Graziano et al 1987). 
Peripheral monocytes can be activated by many regulating factors to 
become macrophages with anti-tumour activity. Granulocyte macrophage-colony-
stimulating factor (GM-CSF) and 1FN stimulate monocytes in vitro to have anti-
tumour activity against tumour cells. Unlike GM-CSF, activation by IFN requires 
another signal such as lipopolysacharides (LPS) to have this action (Grabstein et 
al 1986). Monocytes from normal individuals can be rendered tumourcidal 
following activation by muramyl tripeptide (MTP), with cytotoxic effect on many 
tumour cell lines but not to normal cells (Kleinerman et al 1983). Moreover 
monocytes derived from cancer patients activated by MTP and LPS showed anti-
tumour cytotoxicity against various tumour cells while sparing normal cells. No 
cell type was found to be resistant to tumourcidal activity by activated 
macrophages (Galligioni et al 1993). Macrophage colony stimulating factor 
(MCSF), GM-CSF and IL3 enhance antibody dependent and antibody-
independent cellular cytotoxicity of macrophages, the strongest activator being 
28 
MCSF (Young et al 1990). Macrophages activated by systemic lymphokines can 
eradicate lymph node and lung metastatic lesions in animal models (Fidler et al 
1982). However some sub-populations of macrophages may have a negative 
effect on the immune system (Fu et al 1990). 
Cytotoxic macrophages may be the treatment of choice for certain 
malignant lesions, especially those tumours which resist or escape other 
modalities of treatment. Destruction of tumour cells by macrophages is not 
selective and resistance of tumour cells within the primary or metastatic lesion 
does not develop regardless of the heterogenicity or antigenic properties of the 
tumour cells (Fogler et al 1985; Fidler et al 1985; Galligioni et al 1993). 
I. 6. Tumour Immunotherapy 
Immunotherapy of cancer is based on the concept that tumour cells have 
tumour antigens which can provoke an immune response specifically against 
these cells. In general, immunotherapy has been found to be effective against 
small tumour masses rather than large tumour masses, thus tumour 
immunotherapy is usually used together with other types of treatment. 
Immunotherapy of human cancer was suggested over a century ago before TSA 
had been identified. Today with identification of TSA by monoclonal antibodies 
this type of treatment has become the objective of many clinical trials. Different 
approaches have been attempted to enhance the immune response in tumour- 
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bearing hosts, either specifically against tumour cells or by generalized activation 
of the immune system. 
I. 6. I. Active specific immunotherapy 
Active specific immunotherapy of cancer is based on the concept that 
there is tumour specific antigen or antigens (TSA) present on tumour cells during 
tumour development. These antigens are recognised as non-self and are able to 
stimulate an immune response. In a cancer-bearing host these antigens may be 
present, however, they fail to elicit an immune response. 
A tumour vaccine consists of intact tumour cells or purified extracts of 
tumour cells, which may undergo procedures in vitro in an attempt to enhance the 
immunogenicity of the preparation. This preparation can then be inoculated into 
patients with cancer. Autologous tumour cells are obtained from tumour tissues 
following surgical resection. Allogeneic tumour cells are obtained from tumours 
of the same type but from different patients, this form of vaccine depends on the 
concept that tumour cells of the same histological type have a common TSA. 
Many attempts have been made to augment the immunogenicity of tumour 
vaccines, either by modulating these preparations or adding another antigenic 
materials. These modifications are outlined below. 
Many trials of cancer immunotherapy have used an adjuvant to enhance 
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the immunogenicity of tumour cells (Hoover 1984, 1985). The efficacy of this 
form of modification of tumour cells has been tested in animal models by 
immunizing the animal with modified cells and challenging them by the same but 
unmodified tumour cells. The survival of animals treated with modified cells was 
longer than those treated with non-modified irradiated cells (Wang et al 1967; 
Apffel et al 1966). 
The antigenicity of tumour cells may be modified by different methods. 
Some enzymes may affect the antigen itself in a way that decreases its 
immunogenicity whilst other enzymes may enhance immunogenicity (Pincus 
1981; Seigler et al 1979). Alternatively tumour cell antigenicity may be modified 
by viral infection. Infected tumour cells bear the viral antigen which is highly 
immunogenic, in addition to TSA. The presence of viral antigen in the tumour 
cells enhances the presentation of TSA to the immune system (Boone et al 1978). 
High antibody titre against TSA and positive delayed-type hypersensitivity (DTH) 
were found in mice immunized by recombinant virus contains the coding 
sequence for TSA (Hu et al 1988). 
Isolated cell membrane may have the same antigenicity as the whole cell 
(Neildhart eta! 1988). Mitchell eta! (1988) immunized patients suffering from 
malignant melanoma with mechanical lysates of two melanoma cell lines mixed 
with adjuvant. Identification of TSA by monoclonal antibodies (Mitchell et al 
1986) has enabled isolation and synthesis of TSA (Longenecker et al 1987; 
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Blume eta! 1994) 
Trials of Active Specific Immunotherapy 
Trials of specific immunotherapy had begun by the turn of this century. 
The lack of serious complications and cytotoxic effects of this approach to tumour 
therapy made it possible to carry out trials in humans. The vaccine in early 
immunotherapy trials consisted of tumour cells, tumour cell suspension or 
tumour tissues emulsified or macerated and injected into the skin, subcutaneous 
tissue or abdominal wall (Von Leyden et al 1902; Coca et al 1909; Risley et al 
1911; Kellock 1922). Frozen autologous tumour tissues were used in an attempted 
to prevent tumour implantation while preserving the antigenicity of the cells 
(Stone et al 1955). 
Graham et al (1959,1962) used an autologous vaccine formed from a 
supernatant of tumour cells and Freund's adjuvant, in an attempt to enhance the 
immunogenicity of the tumour cells. Graham reported some improvement in 
patients with squamous cell carcinoma (SCC). Tumour cell extract mixed with 
adjuvant was also used to treat patients with different malignancies. Some patients 
showed a subjective response which could be correlated with DTH reaction of 
the skin to the tumour cell extract (Hughes eta! 1964). 
Finney et al (1960) immunized cancer patients with tumour homogenate 
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from autologous tumour tissues mixed with Freund's adjuvant. Rise in antibody 
titres were seen in all patients. Some patients showed an inflammatory reaction in 
the subcutaneous lesions, and this reaction was followed by regression of the 
tumours. These changes correlated with the rise of antibody titre. 
Depending on the concept that histologically similar tumours have 
common tumour antigen or antigens, a patient with renal cell carcinoma was 
vaccinated with tumour cells taken from another patient. Histological examination 
of the tumour showed no effect of the vaccine, but some precipitate against donor 
tumour could be detected, which could indicate antibody formation against 
autologous tumour cells (Nairn et al 1963). 
In an attempt to enhance the immune response to tumour vaccine, tumour 
cells were coupled to highly antigenic human gamma globulin. Induction of an 
immune reaction against this antigenic protein provoked immune response against 
the coupled cell. Mice with induced squamous cell carcinoma and spontaneous 
adenocarcinoma were injected with this coupled autologous tumour cell vaccine. 
Retardation of tumour growth, necrosis, infiltration with lymphocytes and fibrosis 
of the tumour were seen in the test group, especially those with SCC (Czajkowski 
et al 1966). The same principle was used to create a vaccine for human trials, the 
results were promising, with regression of the tumour in some patients 
(Czajkowski et al 1967; Cunningham et al 1969). 
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The effect of tumour vaccine on tumour cells may be mediated through 
formation of cytotoxic lymphocytes or cytotoxic antibodies against these cells. 
Currie et al (1971) found that the cytotoxic effect of lymphocytes to autologous 
melanoma cells is enhanced by tumour vaccine consisting of irradiated 
autologous tumour cells. On the other hand some studies showed that autologous 
immunization enhanced anti-melanoma antibody formation, the extent of the 
response correlated with the number of tumour cells in the vaccine (Ikonopisov et 
al 1970). 
Irradiated autologous tumour cell vaccine was reported to have negative 
results in patients with malignant melanoma. The survival rate was lower in the 
immunized group compared to the control (McIllmurry et al 1978). McIllmurry 
stated that this sort of treatment may enhance tumour growth. On the other hand 
prolongation of the survival of patients with melanoma treated with allogeneic 
melanoma cell vaccine was reported in another study (Morton eta! 1978). 
Some trials used Bacillus Calmette Guerin (BCG) as adjuvant with tumour 
cell vaccine to increase the reactivity of the immune system against tumour 
vaccine (Morton et al 1978). Other trials used Corynebacterium parvum (C. 
Parvum) as adjuvant due to complications associated with the use of BCG 
(McCune et al 1979). Complete and partial response of metastatic lesions were 
reported following treatment with autologous tumour vaccine plus C. parvum. 
(McCune et al 1981). 
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The efficacy of immunotherapy consisting of BCG and irradiated tumour 
cells treated with neuraminidase was reported by Seigler et al (1979). 
Neuraminidase was used to expose tumour antigen to the immune system. Two 
cases of renal cell carcinoma with poor prognosis (stage IV) showed complete 
remission following treatment with autologous tumour antigen mixed with BCG, 
and another two patients had partial remission (Neidhart et al 1980). 
Guinea pigs with induced metastatic hepatocarcinoma were immunized 
with irradiated tumour cell vaccine and BCG. Examination of pulmonary foci 
showed mononuclear infiltration in the early stages, and histiocyte infiltration 
with fibrosis and central necrosis was noticed later in the test group (Hanna et al 
1981). 
Morales et al (1980) proved the effectiveness in an animal model of 
immunization by irradiated whole cell or cell extract vaccine. Another study in an 
animal model showed that immunization with BCG and irradiated tumour cells 
eradicated dermal tumour deposits and prevented lymph node metastasis (Yarkoni 
eta! 1982). 
Delayed Type Hypersensitivity reaction (DTH) is used to measure the 
cellular immunity against specific antigen, including tumour antigen. 
Immunization of patients with autologous colorectal carcinoma cells and BCG 
increased DTH significantly toward the tumour cells whilst DTH towards normal 
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mucosa did not increase (Hoover et at 1984; 1985). Complete remission in three 
patients and partial remission in another six patients with stage IV renal 
carcinoma was reported following treatment with autologous tumour cells after 
palliative nephrectomy (Scharfe et at 1986). 
Mechanical lysates of two melanoma cell lines with a novel adjuvant were 
used as a vaccine to treat patients with malignant melanoma. Regression of the 
tumours was noted in eight patients out of twenty-two immunized. Cytotoxic 
activity of the peripheral blood leukocytes could be detected in these eight 
patients, unlike unresponsive patients (Mitchell et al 1988). In contrast to these 
promising results, Lamm et al (1991) reported that irradiated tumour cell vaccine 
may enhance the growth of murine bladder cancer and decrease the efficacy of 
BCG. 
The concept of enhancement of antigen presentation by conjugation with 
a strongly immunogenic hapten has been adopted by some researchers. Twenty-
four patients with malignant melanoma were treated with autologous tumour 
vaccine conjugated with hapten. Fourteen patients had clinical evidence of 
inflammation of the melanotic lesions, and the rest of the patients showed 
histological evidence of inflammation (Berd et at 1991). Berd stated that the 
immune response against melanoma antigen was highly augmented by the hapten. 
Encouraging results of tumour vaccine were described by Slingluff et al 
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(1992). Slingluff treated 2,968 patients with stage I melanoma with 
immunotherapy consisting of either three cell lines or a single cell line. The ten-
year survival rate was greater in immunized patients compared to the control 
group. In addition serological activity of immunized patients increased 4.4 fold 
after immunization. Polyvalent multiple tumour cell vaccine was used in patients 
with melanoma by Morton et al (1992). The five year survival rate increased two 
to three fold in the treated patients. Most of the patients showed a prompt 
response to this vaccine. The enhancement of immune response in patients was 
correlated with clinical response. Berth et al (1994) reported increased DTH and 
cytotoxic T-cell reactivity in patients immunized with polyvalent melanoma 
vaccine. 
The use of genetically modified tumour cells as a vaccine is another 
approach to enhance the efficacy of tumour vaccine. Tumour cells transfected 
with cytokine genes were used to increase the ability of the immune system to 
recognize TSA. The idea behind these trials is to maintain high levels of cytokines 
at the tumour site, whilst preventing the side effects of high doses of the 
cytokines. Immunization with transduced tumour cells which express murine 
GM-CSF resulted in potent long-standing and specific anti-tumour immunity and 
regression of metastatic lesions (Dranoff et al 1993; Walcimoto et al 1996; Ellem 
et al 1997). In another trial tumour cells have been transfected with other 
cytokines such as interleukin-2 and interferon genes (Abdel-Wahab et al 1994a, 
1994b). It is reported that this method of cytokine production is more effective 
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than systemic administration of the cytokines (Belldegrun et at 1 9 9 3). 
Transfection of poorly immunogenic tumour with cytokines increased 
immunogenicity and decreased tumourigenicity of tumour cells and induced 
specific immune response against tumour cells (Zitvogel et at 1996b; 
Hollingsworth et at 1996). 
Autologous melanoma cells conjugated with hapten dinitrophenyl (DNP) 
induced inflammatory responses in metastatic lesions which was associated with 
tumour regression. DTH to tumour cells developed in most of the patients (Berd 
et al 1994; Sato et at 1995; Berd et at 1997; Sensi et at 1997). Vaccine consisting 
of antibodies which mimic TSA administered to patients with ovarian carcinoma 
resulted in development of specific humoral and cellular immune responses 
(Wagner et al 1997). In an animal model it has been shown that immunization 
with tumour cells which express co-stimulatory molecules such as B7 induce 
tumour specific immunity to autologous and HLA-matched allogeneic tumour 
cells (Yang et al 1997b). 
I. 6. 2. Active Non -Specific Immunotherapy 
Active non-specific immunotherapy aims to increase the immunological 
reactivity of the host, either humoral or cellular, in a non-specific manner. These 
therapies may increase immunological activity by creating an inflammatory 
reaction which enhances the reactivity between effector cells and antigens, or they 
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may modify the reactivity of the immune cells. 
Many agents have been used for this purpose, such as BCG (Stjernsward 
1966; Houchens et al 1973), C parvum (Woodruff et at 1966; McCune et al 
1978), other bacterial preparations such as polynucleotides (Alexander et at 
1971), and viruses (Herberman et al 1977a). Lipopolysaccharides of Proteus 
valgaris are also found to have anti-tumour effect in an animal model (Mizuno et 
al 1968). 
Pearl (1929) was among the first to find a relationship between active 
tuberculosis infection and malignancy. Pearl reported that the incidence of cancer 
among patients with tuberculosis was less than the normal population. 
The immunological properties and anti-tumour effect of BCG have been 
studied in both animal models and humans. BCG was found to have a number of 
immunological effects: it increases the number of antibody-producing cells, 
enhances humoral immunity against unrelated antigen and enhances cellular 
immunity (Stjernsward 1966; Morton et al 1978; Houchens et al 1973). In 
tumour-bearing hosts BCG was found to augment cell mediated immunity 
(Gutterman eta! 1973), augment macrophage production (Fisher et al 1974) and 
increase NK activity against tumour cells (Herberman et al 1977b). Pre-
sensitization of peripheral blood mononuclear cells by BCG had a cytotoxic 
effect on target tumour cells (Bohle eta! 1993). 
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BCG immunotherapy aims to increase the immunological reactivity of the 
host in a non-specific manner and thus enhance immunity against tumours. The 
effectiveness of BCG as a treatment depends on the immunogenicity of the treated 
tumour and the immunological status of the tumour-bearing host (Creau et al 
1980). 
BCG can be administered by different routes: intravenous, intra-muscular, 
intra-lymphatic and intratumoural. Intravenous administration of BCG can inhibit 
the development of pulmonary metastasis in animals injected with rat sarcoma 
(Baldwin et al 1973). The inhibitory effect of BCG on tumour development was 
also demonstrated in animals with primary tumours (Baldwin et al 1974). 
To avoid the side effect of systemic administration of BCG, BCG was 
given by scarification to patients with stage III and IV melanoma. Reduction of 
relapse rate and improvement of survival were reported (Gutterman et al 1973). 
Morton et al (1974) reported regression of 90% of melanotic nodules injected 
with BCG, whilst 17% of uninjected nodules underwent regression. Intra-pleural 
BCG improved the survival of patients with stage I disease (McKneally et al 
1976; 1977). 
In animal models it was shown that IV administration of C. parvum could 
delay the appearance of tumours, whether the bacteria was injected after or 
before inoculation of tumour cells (Woodruff et al 1966). In mice, intra-dermal 
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administration of C. parvum led to transient inhibition of chemically induced 
tumour (Currie et al 1970). Likhite (1974) referred to the effectiveness of 
subcutaneous administration of C. parvum in animal models. Prolongation of the 
survival of mice with fibrosarcoma injected intravenously with C. parvum was 
also reported (Milas et al 1974). Pimm (1977a) demonstrated the effectiveness of 
local rather than intravenous administration of C. parvum. 
Intra-lymphatic administration of BCG was applied to patients with 
gynaecological malignancies. Patient survival correlated directly with the 
inflammatory reaction in lymph nodes due to BCG injection (Mangan et al 1977). 
Promising results were reported with intravenous and intra-vesical administration 
of BCG following incomplete resection of the tumour in patients with transitional 
cell carcinoma (morales et al 1981; Herry et al 1983). BCG treatment also 
enhanced the effect of subsequent chemotherapy in animals (Hanna 1982). BCG 
has been used to inoculate the site of the vaccination prior to vaccine 
administration. This approach was attempted to enhance the immune reaction to 
the tumour cells at the site of the injection (Livingstone et al 1983; 1985). 
Apart from treatment of superficial bladder cancer by intra- vesicular 
BCG alone, most of the human trials have used BCG as an adjuvant to tumour 
cell vaccine or antigen preparation to treat patients with colorectal cancer (Hoover 
eta! 1984; 1985), metastatic melanoma (Berd et al 1988; 1990; 1991), leukemia 
(Powles et al 1973; Rittch et al 1978; Rosenberg et al 1978) and experimental 
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bladder cancer (Morales et al 1980; Lamm et al 1991, 1995; Bui et al 1997). 
Patients with renal cell carcinoma developed DTH to tumour cells 
following vaccination with autologous tumour cells mixed with BCG (Galligioni 
et al 1997). In clinical trials BCG administered intravesically was effective in 
producing immunity against transitional cell carcinoma of bladder and increased 
the survival in these patients (Lamm et al 1995; Morecki et al 1995; Bui et al 
1997). In murine bladder tumour BCG inhibited tumour growth and was 
associated with signs of tumour regression (Kadhim et al 1997). 
Other types of bacteria or bacterial products have also been used to 
augment the immune reaction against tumours. Heat-inactivated Clostridium 
buyricum produced anti-tumour activity in mice by increasing interferon 
production and enhancing antibody production (Wang et al 1996). Complex 
polysaccarides isolated from bacteria is able to slow tumour growth in mice 
(Donmez et al 1997). 
1. 6. 3. Adoptive immunotherapy 
Adoptive immunotherapy refers to the treatment of cancer by 
administration of lymphoid cells. This type of immunotherapy is a result of the 
fact that cellular mechanisms play a major role in anti-tumour immune response. 
The lymphoid cells may be obtained from the same individual (autologous), from 
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other individuals with tumour or from normal individuals (allogeneic: Powles 
et al 1973). These cells may be sensitized (specific) or not sensitized (non-
specific). The definition of adoptive immunotherapy has commonly been 
extended recently to include treatment with cell products such as interleukins and 
interferons. 
Early trials of adoptive immunotherapy used spleen cells as a source of 
immune cells. Injection of these immune competent cells into patients with 
malignancies affected tumour cells by graft-versus-tumour reaction (Woodruff et 
al 1963). Suppression of tumour growth and regression of established tumours 
were reported in rats treated with intravenous administration of sensitized 
lymphocytes (Delorme et al 1964). 
Adoptive immunotherapy can be achieved by bone marrow 
transplantation. A case of leukemia in progressive phase was treated by bone 
marrow transplantation from six donors following total body irradiation. One 
week after transplantation the patient had complete remission for twelve months, 
chromosomal study showed that leukocytes belonged to the donors (Mathe et al 
1965). Because large amounts of immune cells are required to eradicate tumour 
cells, bone marrow from patients with chronic myeloid leukemia were grafted to 
patients with acute leukemia resistant to chemotherapy (Schwarzenberg et al 
1966). Some patients achieved remission which was attributed by the author to 
the anti-leukemia affect of the grafted leukocytes. White blood cells (WBC) from 
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animals were used in human trials to induce graft-versus tumour reaction (Symes 
et al 1968). 
Complete regression of well established Meth A fibrosarcoma in mice 
could be achieved by IV administration of T-cells from immunized donors 
(Berendt et al 1980). Regression of this highly antigenic tumour could be 
achieved by adoptive immunotherapy only following depletion of suppressor cells 
in the recipients. Mills et al (1983) showed that sensitized T lymphocytes led to 
regression of tumour in T cell-deficient recipients but not in normal recipients. 
This regression was associated with the production of cytolytic T-cells in the 
recipients. Eradication of tumours is carried out by donor T lymphocytes rather 
than host cells (Greenberg et at 1984). 
To identify the sub-populations of T-cells responsible for this therapeutic 
effect, thymectomized mice with disseminated leukemia were treated with non-
cytolytic CD4+ 8 - T-cells which have been sensitized to TSA. These cells which 
are not directly cytolytic to tumour cells were able to eradicate disseminated 
leukemia (Geenberg et al 1985). On the other hand, purified CD8+ cells which 
are specifically cytolytic to tumour cells were found to have limited therapeutic 
effect in tumour rejection. Administration of interleukin-2 (IL-2) with cytolytic T-
cells markedly enhanced the effect of these cells (Greenberg et al 1986). The 
function of IL-2 in enhancement of the cytotoxic effect of the effector cells may 
be through prolongation of the survival of these cells in vivo, rather than 
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generation of new effector cells (Bookman et al 1987). 
One limitation of adoptive immunotherapy is the requirement of large 
numbers of sensitized lymphocytes to achieve tumour regression. Lymphocytes 
can be expanded in vitro by culture in supernatant containing IL-2. These cells are 
more effective in prolonging the median survival time in tumour-bearing hosts 
compared to uncultured cells. Moreover the specificity of the cultured cells was 
maintained during the culture. These cells have the ability to cure mice of 
established disseminated tumour (Cheever et al 1981; Eberlein eta! 1982; Chen et 
al 1990). 
TIL can be activated and expanded in vitro. by IL-2. Patients with 
malignant melanoma were treated with these expanded cells by Aebersold et al 
(1991). T-Lymphocytes (obtained from peripheral blood or bone marrow) were 
also expanded by IL-2 and used for adoptive immunotherapy in animal models 
and human trials (Murphy et al 1993; Porter et al 1994). Adoptive 
immunotherapy may have superiority in treatment of cancer which is resistant to 
cytotoxic effects of anti-neoplastic drugs (Mooney et al 1993). Vaccines 
consisting of tumour cells genetically modified to produce cytokines are able to 
elicit specific anti-tumour immunity, decrease tumourogenicity and induce CTL 
cytotoxicity (Abdel-wahab et al 1994a, 1994b; Zitvogel et al 1996a; Cayeux et al 
1997; Vondrys eta! 1997; Mackensen eta! 1997). 
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The critical role played by DC in initiation of adoptive immunotherapy 
has attracted attention to use DC as a vaccine in tumour-bearing hosts. Reduction 
of metastatic nodules was reported following treatment with sensitized DC in 
humans and animal models (Hsu et al 1996; Nair et al 1997; Yang et al 1997b). 
Vaccines consisting of modified DC to produce certain cytokines or to express 
surface proteins were also evaluated as adjuvant immunotherapy in animal models 
(Zitvogel et al 1996c; Kim et al 1997). 
1. 6. 4. Passive Immunotherapy 
Passive immunotherapy is the oldest form of cancer immunotherapy. This 
form of immunotherapy involves administration of a serological component 
which has a direct or indirect anti-tumour activity. This includes not only 
antibodies but also complement, lymphokines or other factors in the circulation 
which have an anti-tumour effect. Most patients with localized malignancy have 
antibodies in their serum against tumour antigens. Progression of the disease is 
associated with disappearance of the antibodies from the sera of these patients 
(Lewis et al 1969). 
There are three sources of human sera or plasma used in human 
immunotherapy trials : 
1. Plasma from normal donors (Davis 1947; Moore et al 1957); 
2. Plasma obtained from donors who are immunized with normal or 
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tumour tissues (Brittingham 1960; Laszlo et al 1968).; 
3. Plasma taken from patients in remission or who underwent spontaneous 
regression (Ngu et al 1967; Horn et al 1971). 
The anti-tumour activity of antibodies can be categorized as: 
1. Antibody-mediated cytotoxicity. The effector cells recognize the Fc 
portion of antibody on the tumour cells which leads to lysis of the tumour cells 
(Kipps et al 1985); 
2. Complement-mediated cytotoxicity. The complement cascade is 
activated by immunoglobulin (Ig) attached to tumour cells. This leads to tumour 
cell destruction (Bumstein et al 1980); 
3. Direct effect of Ig on special structures on the surface of tumour cells 
which plays a vital role in cell survival (Masui et al 1984; Change et al 1993); 
4. Production of anti-idiotypic antibody which have configurations similar 
to tumour antigen. These antibodies may induce auto-antibodies or cellular 
toxicity against that antigen (Forstrom et al 1983; Saleh et al 1993; Wagner et al 
1997); 
5. Antibodies may act as a mediator to deliver other agents to tumour cells 
(Deguchi et al 1986). 
Anti-tumour antibodies could be produced in rabbits or sheep sensitized 
to tumour cells. Injection of experimental animal with tumour cells, together with 
these antibodies could prevent tumour growth (Buinauskas et al 1959). 
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Regression of malignant melanoma was reported in a patient following whole 
blood transfusion taken from patients who underwent spontaneous regression 
(Sumner et. a/ 1960). Ngu et al (1967) treated two patients with Burkitt's 
lymphoma with plasma taken from patients who underwent spontaneous 
regression. One of the patients had marked anti-tumour effect and the other had 
moderate improvement. 
Hyper-immune gamma globulin may be obtained by immunizing animals 
with purified antigens from solid cancer or leukemic tissues. Patients with solid 
tumours and leukemias were treated with this immunoglobulin. Most of the 
patients with leukemia achieved remission, and all patients with solid tumours had 
subjective improvement (De Carvalho 1963; Murray 1965; Newman eta! 1977). 
The development of monoclonal antibodies has allowed the use of such 
antibodies as passive immunotherapy, especially following the identification of 
tumour antigens. These monoclonal antibodies can be directed against tumour 
cells without affecting normal cells (Badger et al 1983). Mice with transplanted 
leukemia were immunized with monoclonal antibodies directed against T-cell 
differentiation antigen (Thy-1.1). Immunization with monoclonal antibodies and 
complement led to cure of the leukemia in a significant number of the mice 
(Burnstein et al 1980). Patients with cutaneous T-cell lymphoma were treated 
with murine monoclonal anti-T cell antibodies. Regression of skin and lymph 
node lesions was reported. Some patients may have developed anti-monoclonal 
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antibodies against murine antibodies which may be the cause of unresponsiveness 
in some instances (Miller eta! 1981, 1983). 
While some have shown that murine monoclonal antibodies directed 
against human tumour antigen can be administered safely to patients with 
malignancies (Sears et al 1982), other studies have reported some side effects of 
such treatment, for example pulmonary toxicity (Foon et al 1984). Formation of 
blocking factors in the serum of treated patients has also been described (Catane 
eta! 1988). 
To avoid the hazard of anti-mouse antibody formation, some have tried to 
develop human monoclonal antibodies (Hale et al 1988). Hale reported some 
improvement in two patients with non-Hodgkin's lymphoma treated with such 
antibodies. Koda et al (1990) generated monoclonal antibodies against colonic 
cancer using human nodal lymphocytes. These antibodies were found to be 
cytotoxic to human colonic cancer cells in the presence of complement (Change 
eta! 1993). 
Antibodies which are directed to the surface antigen of tumour cells can be 
used as a carrier for cytotoxic or radioactive agents (Vial et al 1957; Ghose et al 
1972, 1975; Deguchi et al 1986; Waldmann et al 1991). Fragments of 
monoclonal antibodies were also used in immunochemotherapy. Immunotoxin 
consisting of Fab fragment of monoclonal anti-CD22 antibodies coupled to 
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deglycosylated ricin were used to treat patients with B-cell lymphoma (Vitetta et 
al 1991). Partial response was achieved in 38% of the patients. Coupling of 
antibodies to Staphylococcus aureus entertoxin was attempted to direct T-cell 
activity against tumour cells carrying these coupled antibodies. Administration of 
this conjugation to mice previously inoculated with lymphoma cells improved the 
survival in the treated group (Ochi et al 1993). 
Antibodies which mimic TSA administered to patients with advanced 
tumour may result in development of cellular and humoral immunity to TSA 
(Wagner et al 1997; Durrant et al 1997). Monoclonal antibodies which can bind 
to tumour cells and to specific receptors on T-cells are able to increase the 
immunogenicity of tumour cells and generate efficient immune responses (Guo et 
al 1997). 
1. 7. Summary 
This review shows that the immune system plays an important role in 
controlling certain malignant growths. Immunological protection against cancer is 
mediated predominantly by cellular immunity. Tumour infiltration by immune 
cells and clonal expansion of TIL in situ indicates the presence of an immune 
response against tumour cells. However in tumour-bearing subjects induction and 
maintenance of a sufficiently large immune response is required for effective 
immunity against tumour cells. Tumour immunotherapy aims to enhance the 
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immune response against tumour cells by increasing the immunogenicity of 
tumour cells, improving presentation of TSA to the immune system or increasing 
the reactivity of the immune system. This thesis aims to examine a role of DC in 
detecting vaccine-induced immune responsiveness to induced skin carcinoma in 
mice, specifically whether DC may be a marker of such a response. 
51 
CHAPTER 2 
MATERIALS AND METHODS 
2. 1. Animals 
Male and female BALB/c mice were obtained from the University of 
Tasmania animal house with approval of the Animal Ethics Committee. The animals 
were kept in the Department of Pathology animal house and fed food and water ad 
libitum. Mice were between 6-8 weeks old at the beginning of the experiment and 
were kept in groups of 7-10. The mice were observed closely on a daily basis. 
2. 2. Carcinogen Treatment 
Benzo-a-pyrene (BP) was obtained from Serva USA (Lot No 30091). Every 
second week 10 ml of 0.5% BP in acetone solution was prepared (50 jig of BP 
dissolved in 10 ml acetone). All precautions were taken when working with BP 
either in preparation or experimentation. Double gloves, surgical mask and 
laboratory coat were always worn. 
Animals were treated in a room specifically for carcinogen use and all waste 
(sawdust, pipette tips, tissues, etc.) were disposed of in labelled rubbish bags and 
52 
burned. The dorsal trunk of each mouse was shaved and 201.11 of 0.5% BP solution 
applied. Mice were treated twice a week for twenty-four consecutive weeks. 
2. 3. Separation of Mice into Test and Control Groups 
Following carcinogen application visible changes in the skin were recorded 
every week. By the end of the twenty-fourth week mice developed either single 
(Figure 1, page 89) or multiple (Figure 2, page 90) tumours. After the development 
of tumours, mice were divided into two groups: control and test. Seven mice were 
placed in each cage, the cages were given numbers from 1-8. The mice were marked 
by painting the ears with different colours, for example right ear red cage l(RR 1), 
left ear red cage 1 (LR 1), both ear red cage 1 (BR 1). The mice in both groups were 
chosen to have similar tumours regarding size. 
2. 4. Anaesthesia 
Mice were anaesthetized by intra-peritoneal injection of 10% phenobarbitone 
solution (Boehringer Ingleheim). The dose was adjusted according to the weight of 
the mouse. Mice were kept in a special cage until they were anaesthetized. 
Ten percent phenobarbital solution was prepared by adding 5 ml phenobarbital 
to 45 ml phosphate buffered saline (PBS; Oxoid England Lot R007531-001). The 
solution was sterilized by passage through a Millipore filter. Five ml aliquots were 
stored at 4°C. 
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2. 5. Tumour Excision 
Mice were placed on cork boards covered with sterilized tissues. The dorsal 
trunk and skin surrounding the tumour was shaved with electrical clippers and 
sterilized with 70% alcohol. A whole tumour in the case of mice with multiple 
tumours, or part of the tumour in the case of mice with single tumours was excised 
using scalpel and forceps. Bleeding was stopped by applying a cotton ball at the site 
of the wound. The wound was then closed with stainless steel auto-clips (Figure 3, 
page 91). Three to seven clips were used for each mouse depending on the size of 
the wound. All procedures were carried out under sterile conditions. 
Tumour was placed in a sterile yellow top universal container containing 
Modified Hank's Medium (MHM: Sigma, USA, Lot H6136) and transferred to a 
laminar flow cabinet. The weight of the tumour tissues was recorded. 
2. 6. Disaggregation of Tumour 
2. 6. I. Mechanical Disaggregation 
In the laminar flow cabinet tumours were transferred to 100 mm petri dishes 
containing Modified Hank's Medium. The tumours were trimmed of necrotic tissue, 
fat and other non-tumour tissues and rinsed three times in Modified Hank's 
Medium. Tumour was then transferred to another petri dish containing an equal 
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volume of 0.1% trypsin solution ( ICN, USA, Lot 47999 ) and 0.2% EDTA (Univar 
Australia). Mechanical disaggregation was carried out using scalpel and forceps in a 
cross-cutting motion until the tumour was fragmented into small pieces (1-2 mm). 
Care was taken not to exert excessive pressure with the scalpel and forceps and not 
to scratch the petri dish. 
Mechanically disaggregated tumour cells were obtained by collecting the 0.1 
% trypsin solution and 2% EDTA solution used to rinse the tumour tissues during 
mechanical disaggregation. This solution was passed through a syringe containing 
sterile gauze to remove any lumps. The filtered material was placed into a yellow top 
sterile universal container and centrifuged at 160 g for 10 minutes. The pellet was 
resuspended in 0.5 ml of RPMI medium (ICN, USA) after washing the pellet twice 
with RPMI medium. A sample was taken and cell viability was determined using 
eosin-Y dye exclusion. 
2. 6. 2. Enzymatic Disaggregation 
The minced tumour tissues (from 2. 6. 1.) were transferred to a sterile yellow 
top universal 50 ml container by pipette. Equal volumes of 0.1% trypsin and 0.2% 
EDTA were added to tumour tissues. Volumes were dependent upon the weight of 
the tissues, i.e. 10 ml trypsin and EDTA solution per gram of tissue. The tumour 
tissue was then incubated at 37 0 C on an orbital shaker (100 rpm) for 40 minutes. 
Under sterile conditions the supernatant was harvested and fresh trypsin and EDTA 
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solution added. The tissue was incubated for a further 40 minutes and the above 
steps repeated. Following harvesting the supernatant was filtered through sterile 
gauze to remove tissue lumps. Five ml of RPMI was added to the filtered harvest to 
dilute the enzyme solution. The cell suspension was then centrifuged at 160 g for 10 
minutes. The supernatant was discarded and the pellet resuspended in 5 ml RPMI. 
This step was repeated, and the pellet was resuspended in 500g1RPMI. 
2. 7. Sterility 
One harvest from each tumour was placed in a culture flask with culture 
Medium (Modified Hank's Medium). The culture flask was incubated for five days 
at 37 0 C in a humidified atmosphere of 5% CO2 in air. Following incubation the 
flask was checked for bacterial growth. 
2. 8. Cell Number and Viability 
Cell viability was assessed using eosin-Y dye exclusion (0.1 % in PBS). A 
10g1 sample of cell suspension was mixed with 101.t1 of eosin-Y dye, and placed on a 
haemocytometer. Cells were examined under light microscopy. Viable cells 
excluded the stain, whilst dead cells did not. The cell count per ml and the viability 
were calculated according to the formula: 
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Cells /m1 	= 	N * 2 * (25/X ) * 10 4 
where N 	= 	Number of the cells counted 
X 	= 	Number of the squares counted 
% viability 	= 	No of viable cells / total cells * 100 
2. 9. Cryopreservation 
All cryopreservation procedures were performed in a laminar flow cabinet 
using sterile technique. Freezing medium was prepared immediately prior to cell 
freezing and placed in ice. The freezing medium contained 20% dimethylsulphoxide 
(DMSO; Sigma USA Lot 1344666), 20% foetal calf serum (FCS: ICN. USA) and 
60% RPMI (ICN USA). Cells were suspended and aliqouted in 500 p,1 into 
cryopreservation tubes (Simport, Canada) and placed in ice. An equal volume of 
freezing medium was added dropwise, doubling the volume each time (that is, 1 
drop, 2 drops, 4 drops, 8 drops etc.). Tubes were wrapped in cotton wool and placed 
in a -80°C freezer. Storage time was between one and six weeks. 
2. 10. Cell Thawing 
Cells were thawed in a 37°C water bath until a small lump of ice remained. 
Cells were then transferred to a 10 ml centrifuge tube on ice in the laminar flow 
cabinet. Ten ml RPMI was added gradually. The cells were centrifuged at 160 g for 
10 minutes. The supernatant was discarded and the pellet washed twice with Hank's 
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Buffered Salt Solution (HBSS; Sigma USA). The cell pellet was resuspended in 500 
IA of HBSS and cell number and viability determined. An additional 5001.11 of HBSS 
was added and the cell suspension taken immediately for radiation treatment. 
2. 11. Cell Irradiation 
Cells where irradiated at the Holman Clinic, Royal Hobart Hospital. The tubes 
were kept at room temperature and placed in an open box filled with water to the 
level of the cell suspension. A cone (70 X 70 mm 2 ) was placed over the tubes in the 
box touching the bottom of the box, the test tube directed over the cone. A dose of 
25.00 Gy (1 Gy = 100 Rads) was given to the cells over 4.25 minutes. The tubes 
were then transferred to a laminar flow cabinet to check cell viability. 
2. 12. Vaccination 
Each mouse was photographed and given a number according to the colour of 
ear painting and the number of the cage. The weight of each mouse either in control 
or in the test groups was recorded. 
The injection site was shaved with electrical clippers and swabbed with 70% 
alcohol, and the tumour cells were injected subcutaneously. The site of vaccination 
was chosen to be away from the tumour to detect any implantation of the tumour 
cells from the vaccine. The site of vaccination was recorded. The vaccination was 
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repeated every week for three consecutive weeks. The control group was injected 
with equivalent volumes of HBSS alone. 
2. 13. Tumour Size 
Comparison of tumour size between the mice was indicated by measuring the 
largest diameter of the tumour before and after giving the three vaccines. The 
diameter was measured by a measuring tape placed beside the tumour whilst 
photographing the mice. 
2. 14. Killing the Animals 
By the end of the third week the mice were killed by cervical dislocation. 
Photographs were taken of each mouse either in the control or test groups showing 
the tumour clearly. The tumour tissues from the control and test groups were 
resected and placed in labelled tubes containing formalin, for later histological 
examination. 
2. 15. Histological Examination 
Tumour specimens from treated and control mice were surgically excised, 
fixed in 10% formalin and embedded in wax. The tissue blocks were sectioned at a 
thickness of 5 gm. Several tissue sections from each tumour (5- 20 sections) were 
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stained with haematoxylin and eosin. The slides were examined under light 
microscopy by two persons working together using a 2-head microscope. The degree 
of tumour infiltration leukocytes and the degree of tumour necrosis were recorded by 
the observers as mild, moderate and marked. The degree of infiltration and necrosis 
was categorized as follows : 
LEUKOCYTE INFILTRATION: 
mild 	 <10 cells / HPF 
moderate 	10- 50 cells / HPF 
marked 	> 50 cells / HPF 
NECROSIS: 
mild 	 Necrosis involving < 10 % 
moderate 	Necrosis involving 10-40% 
marked 	Necrosis involving > 40% 
2. 16. Immunostaining Procedure 
Formalin fixed paraffin embedded tissues were placed in freezer for 90 
minutes (<40 °C). Paraffin sections were cut at 3 microns, picked up on APTS 
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coated slides (page 66) and dried at 56°C for 2 hours and then overnight at 37°C. 
The pre-stored slides were placed in a 56°C oven for 10 minutes prior to dewaxing. 
The slides were dewaxed in 2 changes of xylene for 4 minutes each and rehydrated 
through a descending series of alcohol of 100%, 95% and 70%, 2 minutes each and 
in running tap water for another 2 minutes and then rinsing in DDW for 2 minutes. 
Slides were transferred into plastic slide racks (the racks were completely 
filled with slides, empty spaces were filled with blank slides), sections were 
immersed into plastic troughs containing the Target Retrieval Solution (Dako Code 
No. S 1700). All slides were covered with the solution and troughs were covered 
with the lids and transferred into microwave at 500 W for 8 minutes. After 8 
minutes the racks were agitated few times and microwaved for another 8 minutes at 
500 W, then the troughs were removed from the microwave and allowed to cool for 
20 minutes at room temperature. Slides were rinsed under running water and 
transferred into TRIS buffer (0.05M) where they were incubated overnight. 
The slides were incubated at room temperature for 60 minutes in primary 
antibodies (anticow S 100, Dako, Z 311) diluted 1: 100 in diluent (5% bovine 
albumin, solution in 0.05 M TRIS buffer, CSL S 31202) , while for negative control 
slides antiCow S 100 was substituted with negative control reagent (Biogenex Ca 
94568) and used at the same dilution. After incubation with primary antibodies 
slides were washed with 0.05 M TRIS buffer three times five minutes each using a 
squeeze bottle. The slides were then incubated at room temperature for 60 minutes 
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with secondary antibodies (biotinylated anti-rabbit irnmunoglobulin, Biogenex HK 
326-UR) at a dilution of 1: 100 in 5% albumin solution (bovine albumin, CSL S 
31202) in 0.05 M TRIS buffer (page 67). After washing with 0.05 M TRIS buffer as 
for primary antibodies slides were incubated for 60 minutes in alkaline phosphatase 
conjugated streptavidine (Biogenex HK 321-UK) at a dilution of 1: 40 in 0.05M 
TRIS buffer. 
The slides were washed with 0.05M TRIS buffer for 15 minutes and filtered 
substrate (page 68) was applied for 12 minutes before washing the slides with 
deionised water to remove the substrate. The slides were then transferred into 
appropriate staining racks and washed in running water for 2 minutes and then 
counterstained in Mayer's Haematoxylin for 2.5 minutes. After washing in running 
water the slides were blued in ammoniated water for 30 seconds and then washed 
again in running water and dried in a 76 0C oven for 10 minutes. The slides were 
then mounted, overslipped using Eulcitt (Carl Zeiss, 00 20 20) and dried on a hot 
plate for a few minutes. 
2. 17. Identification and Counting of Dendritic cells 
The dendritic cells were recognised by their S100-positive red cytoplasm, and 
by cell morphology. Cells were only counted if the nucleus was identified. Other 
S100-positive material was excluded by their morphology. The degree of dendritic 
cell infiltration was assessed by two persons separately, each counting five high 
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power fields (magnification x200) randomly selected from the tumour tissue and 
adjacent surroundings. An average of ten high power fields was calculated for each 
section. 
2. 18. Sterile Technique 
All disaggregation and other procedures were carried out in a biological safety 
cabinet. Ultraviolet light was switched on for fifteen minutes before using the 
cabinet. The cabinet was swabbed with 70% alcohol before starting and after 
finishing each procedure. All sterilized solutions and containers were opened in the 
cabinet and were closed before taking them out. Sterile forceps were used to take 
pipettes and the other equipment out of their sterile containers. All pipettes were 
placed on special racks during the procedure to keep them sterile. 
Glass pipettes were plugged with cotton wool and put in aluminium containers 
which were sealed by autoclave tape. The pipettes were sterilized in an autoclave at 
120°C for 20 minutes. The gauze used for filtering the disaggregated cells was 
prepared and sterilized as follows. The gauze was cut into small pieces (2 cm X 2 
cm). The pieces were then folded many times and placed in aluminium foil and 
sealed by autoclave tape. The pieces were placed into autoclave bags and sterilized 
in an autoclave at 120°C for 20 minutes. Pipette tips were placed into small glass 
containers and sterilized in the autoclave as for the pipettes. Surgical instruments 
were placed in sealed autoclave bags and autoclaved at 120°C for 20 minutes. All 
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glassware used was washed in detergent followed by rinsing with tap water, then 
soaked in distilled and double distilled water. 
2. 19. Media and Solutions 
Hank's Balanced Salt (HBS, Sigma, USA, Lot H6136) 
Component gil- 
Calcium Chloride 0.185 
Glucose 1.000 
Magnesium Sulphate 0.09767 
Potassium Phosphate Monobasic 0.060 
Potassium Chloride 0.400 
Sodium Chloride 8.000 
Sodium Phosphate Dibasic 0.04788 
Phenol Red Na 0.011 
Modified Hank's Medium (MHM) 
800 ml of autoclaved water was placed in a 2L flask with a magnetic stirrer. 
HBSS powder was added to the water and stirred until dissolved. 0.35 g sodium 
bicarbonate (NaHCO3) was added and the pH adjusted to 7.40 ± 0.05 with HC1 (1M) 
and/or NaOH (1M). The solution was filtered by Millipore filtering (0.45 gm), and 
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stored in 500 ml lots at 4°C. 
Phosphate Buffer Saline (PBS, Oxoid England) 
100 ml of autoclaved water was placed in 200 ml flask. One tablet of PBS salt 
was added to the flask and stirred until it dissolved. 
Trypsin Solution 0.1% 
To 100 ml of PBS 0.1 g sucrose and 0.1 g trypsin were added. The pH of the 
solution was adjusted to 7.4 ± 0.05 with HC1 (1M) and/or NaOH (1M). The solution 
was sterilized by millipore filtering (0.2 gm) and stored in 50 ml yellow top 
universal containers at -20 0 C. 
EDTA Solution 0.2% 
EDTA solution was prepared by adding 0.2g EDTA to 100 distilled water. The 
flasks were placed on an electrical stirrer until EDTA dissolved and the pH of the 
solution was adjusted to 7. 4 + 0.05 with HC1 (1M) and/or NaOH (1M). The solution 
was sterilized by millipore filtering (0.2 gm) and stored in 50 ml yellow top 
universal containers at - 20 0 C. 
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RPM! 1640 Medium 
RPMI 1640 was obtained from ICN, USA and stored at 4° C. 2.5 ml of 
Penicillin (5,000 IU/m1)/Streptomycin (5mg/ml, ICN, USA) and 5 ml of 3% L-
glutamine were added to 500 ml of RPMI. 
Foetal Calf Serum (FCS, ICN, USA) 
Foetal calf serum was inactivated by incubation at 56° C for 30 minutes and 
stored at 4° C. 
Freezing Media 
10 ml freezing media was prepared each time as follows. Six ml (60%) RPMI 
1640 with antibiotic (5 m1/1, Penicillin 5,000 IU/ml and Streptomycin 5 m1/1) was 
placed in each of several yellow top universal containers and these were placed in an 
Esky filled with ice. Two ml (20%) FCS was added to the each containers and kept 
in the Esky until the temperature reduced. Two ml (20%) of DMSO was added to 
each container whilst on ice and shaken several times. 
3-Aminopropyltriethoxysilane (APTS) coating of microscope slides 
8 ml of APTS was added to 400 ml of acetone, a microscope slide rack was 
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loaded with clean dry microscope slides, the slides were immersed in APTS solution 
for 2 minutes then rinsed with two changes of fresh distilled water. Slides were 
drained and dried over night at room temperature. 
Stock 0.5 M Tris buffer pH 7.6 
121.12 gm of Trishydroxy-methyl-amino-methane was dissolved in 
approximately 1600 ml of deionised water, 180 gm of sodium chloride was added 
and dissolved and pH was adjusted to 7.6 using 70 ml of concentrated HC1. The 
volume was made up to 2 L using deionised water. 
0.05 M Tris buffer pH 7.6 
The working solution of 0.05 M Iris buffer pH 7.6 was made by adding 
deionised water to 100 ml of 0.5 M Tris buffer pH 7.6 making the final volume up to 
1L. 
Primary antibodies, antiCow S100 (1: 100) 
2 ml of 0.05 M TRIS buffer 
100 pl of bovine albumin ( CSL S 31202) 
20 IA of antiCow S 100 (Dako, Z 311) 
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Negative control reagent 
2 ml of 0.05 M TRIS buffer 
100 Al of bovine albumin ( CSL S 31202) 
20 pi of negative control reagent (Biogenex Ca 94568) 
Substrate 
Solution 1:  
- 0.2 M Propanediol buffer 
-1.514 gm of 2-Amino-2-Methyl-1,3-propanediol 
(Merck, 801464) 
-72 ml of deionised water 
-0.05M Tris-HCL saline buffer pH 9.7 
-1.211 gm of Tris Base (Boehringer No 604203) 
-200 ml of deionised water 
-2.4 gm Sodium chloride (Ajax Chemicals-Univar-465) 
-0.11 gm of Levamisol (Sigma L 9756) 
The propandiol buffer was mixed with the Tris-HCL buffer, sodium chloride 
and Levamisol were added and the solution was stored in the fridge. 
Solution 2:  
-10 mg of Naphthol AS-B1 phosphate (Sigma, 2250) 
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-120 pl of N,N-Dimethylformamide (Sigma, D-4254) 
-Naphthol AS-B1 phosphate was dissolved in N,N 
-Dimethylformamide in the fume cupboard. 
Solution 3:  
-40 pl of 5% New Fuchsin 
-5 gm of New Fuchsin (Sigma N 0638) 
-100th! of 2N of HC1 
-100 of 4% Sodium Nitrite 
-4 gm of Sodium Nitrite (Ajax Chem-Univar 492) 
-100 pl of deionised water 
New Fuchsin was mixed with the freshly prepared sodium nitrite in a cold 
environment (-80 0C freezer) for one minute. 19.5 ml of solution 1 was mixed with 
120 gl of solution 2, solution 3 was then added and pH was adjusted to 8.7 using 2N 
HC1. The working solution (substrate) was mixed and filtered. 
2. 20. Statistical and Graphical Analysis 
The Excel and Macintosh Statview program were used for statistical analysis 
and graph drawing. The significance (P value) was calculated using the same 
program> P values of <0.05 was recognised as indicating a statistically significant 
difference. 
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CHAPTER 3 
RESULTS 
3. I. Treatment with Benzo-a-pyrene 
Benzo-a-pyrene was applied in 20 IA volumes twice weekly to the dorsal 
surface. Two days after carcinogen application visible changes on the skin surface 
could be seen. These consisted of erythema and hair loss. Four weeks after the 
application of carcinogen, papillomas had begun to appear. By the tenth week 
approximately 50% of the mice had one or more discrete papillomas. Fungating 
tumours started to appear after ten weeks, and by week twenty four almost all mice 
possessed multiple or single tumours. 
The growth of the tumours was not limited to the site of carcinogen 
application, but occurred at other sites (e.g. neck, abdomen and leg). 
3. 2. Surgical Resection of the Tumours 
3. 2. I. Mortality and morbidity 
Some mice haemorrhaged during resection of the tumour, especially those 
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mice with infiltrating tumours. Four mice died one to two hours following the 
operation as a result of bleeding. Another three were killed during the operation due 
to uncontrolled bleeding. Those that recovered from the operation proceeded to do 
well. Most mice returned to normal movement and activity within a day. 
3. 2. 2. Wound Healing and Infection 
The wound infection rate following the surgical procedure was very low. Two 
out of fifty mice suffered from infection. In one the infection was severe, and the 
mouse was killed. Wound healing at the site of the operation occurred within four to 
seven days. Some mice showed delayed wound healing, especially those with 
necrotic tumours or with a wide wound surface. 
3. 2. 3. Anaesthesia 
Phenobarbital at a concentration of 10% VN was used to anaesthetize the 
mice. Mice were given one to one and a half times the recommended dose. The mice 
slept ten to fifteen minutes following the anaesthezia and revived after thirty to fifty 
minutes. Out of 75 mice anaesthetized for tumour resection only two died as a result 
of anaesthezia. 
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3. 3. Disaggregation of Tumour 
3. 3.1. Mechanical Disaggregation 
Mechanical disaggregation was initially used to prepare the vaccine due to the 
uncomplicated and fast method. However, mechanical disaggregation of tumour 
tissues using scalpel and forceps yielded a low percentage of viable cells (30-60 %). 
This low viability may have been in part due to the aggressive mechanical procedure 
killing the cells. However tumour tissue is also mixed with necrotic tissue which 
may have been a contributor to the low cell viability. Thus the viability of 
mechanically disaggregated cells depended on the condition of the tumour before 
resection. 
Cells obtained by this method were mixed with red blood cells (RBC) and 
white blood cells (WBC) contributing up to 30% of the total cells. Due to the low 
viability of tumour cells obtained by mechanical disaggregation and the presence of 
a high percentage of RBC and WBC, the tumour cells obtained using this method 
were not used to prepare the vaccine. 
3. 3.2. Enzymatic Disaggregation 
Enzymatic disaggregation of tissues yielded a higher cell viability than the 
mechanical method (Figure 11, page 103). The percentage of cell viability obtained 
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by enzymatic disaggregation ranged from 60% to 90%. The harvest cryopreserved 
for later use as a vaccine had a viability greater than 80%. Harvests with low 
viability (<60% ) and large amounts of cell debris were excluded. 
The centrifugal force used in harvesting cells was found to be critical for cell 
viability. Viability decreased and harvests contained large amounts of cell debris 
when 300g, 240g and 200g were used. The optimum force used was 160 g. The cell 
viability from the first harvest was always low despite the low centrifugal force (160 
g), due to the presence of necrotic tissue. However with successive harvests cell 
viability increased. 
Cells were washed twice with culture media following harvesting to remove 
the enzymes. Washing the cells did not affect cell viability as the viability before and 
after washing was not significantly different ( Figure 12, page 104). 
The sterility of the technique was tested by culturing one or more of the 
harvests for several days to detect any evidence of bacterial growth. The culture 
flasks were tested every day for seven days. One flask contained bacterial growth 
which was excluded from the experiment. No bacterial growth could be detected in 
the other flasks. 
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3. 4. Cry opreservation 
The cells were cryopreserved immediately after preparation to ensure viability 
was as high as possible. Cryopreservation caused a decrease in cell viability of 10 - 
30%. 
3. 5. Cell Irradiation 
Radiation of the cells did not affect the viability of the cells significantly 
(Figure 13, page 105). No tumour growth was noticed at the site of vaccine 
injection which indicated that the X-ray dose was enough to eliminate the ability of 
the cells to divide and to prevent any growth of implanted cells. 
3. 6. Vaccination 
Both the control and test groups were vaccinated. The test group was 
vaccinated with tumour cells mixed with HBSS while HBSS alone was used to 
vaccinate the control group. Vaccination of the control group by HBSS eliminated 
the possibility of an HBSS effect on tumour growth and allowed the exposure of 
both groups to the procedure of vaccination. 
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3. 7. Site of Vaccination 
The vaccirie was injected subcutaneously, and the site of the vaccine was 
chosen to be away from the site of tumour growth. This allowed the detection of any 
tumour implantation at the injection site. No tumour growth could be detected at the 
site of vaccination in all mice treated by the vaccine. 
3. 8. Infection at Injection Site 
No infection could be detected at the site of vaccination in the controls 
(vaccinated with HBSS) or test group (vaccinated with irradiated cell vaccine in 
HB SS). 
3. 9. Tumour Infiltration by Dendritic Cells 
Mice in the tested group were treated with irradiated tumour cell vaccine in 
HBSS once a week for three consecutive weeks while the control was treated with 
HBSS alone in identical schedule. The effect of the vaccine on the tumour was 
measured by comparing the degree of tumour infiltration by DC. The DC average 
per 10 HPF (magnification x200) ranged from 1.8 to 24.4 cells with the mean of 
10.5 ± 6.5 cells in the test group while in control group the DC average ranged from 
0.3 to 8.7 cells with the mean of 3.9 ± 2.9 cells, the difference in DC infiltration 
between the two groups significant at P < 0.05 (anova: single factor). The degree of 
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tumour infiltration by DC in the test group and control group is shown in Table 7&8 
(page 87, 88). Dendritic cells were observed amongst the tumour cells and in the 
stroma surrounding the tumour tissues. DC appeared more rounded with loss of the 
dendrites (Figure 7&8, page 99, 100). 
3. 9. 1. DC Infiltration and Tumour Size 
The difference in tumour size before and after administration of the vaccine 
was calculated by measuring the largest diameter of the tumour (Figure 3, page 91). 
The difference in diameter of the tumour before and after vaccination for the test and 
control groups is illustrated in Table 2&3 (page 82, 83). 
No correlation was found between tumour size and the degree of infiltration by 
DC (correlation co-efficient 0.037 and P > 0.05; F-test). Some mice with marked 
infiltration showed an increase in their tumour size while others had a stable tumour 
size or a slight decrease in tumour size. The correlation co-efficient between DC 
infiltration and the difference in tumour size before and after vaccination is 0.123 (P 
> 0.05; F-test). There was no significant difference between the control and the test 
groups regarding size of tumour. The mean tumour size before and after vaccination 
in the test group was 13.2± 3.9 and 16.2 ± 6.2 respectively (P > 0.05; t-test), and in 
the control group 15.6 ± 5.0 before and 18.0 ± 6.1 after vaccination (P > 0.05; t-test). 
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3. 9. 2. DC Infiltration and Vaccine Dose 
Mice received three doses of tumour cell vaccine with an average range 
between 1.5 and 3.7 X 10 5 tumour cells in the three vaccines (Table 4, page 84). No 
correlation was found between the dose of the vaccine and the degree of tumour 
infiltration by DC. The correlation co-efficient of dose of tumour cells vs. the degree 
of tumour infiltration by immune cells was 0.33 and P> 0.05 (F-test) indicating no 
significant correlation between dose of vaccine and degree of DC infiltration of 
tumours. 
3. 10. Tumour Infiltration by non-DC Leukocytes 
Other tumour-infiltrating immune cells consisted of lymphocytes, 
macrophages and neutrophils, however lymphocytes comprised the majority of 
infiltrating leukocytes. The difference in leukocyte infiltration between the two 
groups was significant. In 70.5% of the control group the infiltration was mild 
compared to 23.5% in the test group. On the other hand 53% of the mice in the test 
group had marked infiltration compared to 12% in the control. The percentage of 
mice with moderate infiltration in test and control groups was 23.5 and 17.5 
respectively (Table 1, page 81; Figure 4 a,b,c & 9 page 92,93,94 &101). The 
difference between both groups was significant (X 2 = 6.41 and P < 0.05; chi sq.). 
Mice in test and control groups were divided into three groups according to the 
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degree of non-DC leukocytes infiltration: mild, moderate and marked. The mean of 
DC infiltration in each of the three groups was 4.5 ± 3.8, 7.4 ± 5.5 and 11.1 ± 6.9 
respectively, the difference of DC infiltration between three groups was significant 
(P < 0.05; anova: single factor). 
Degree of non-DC 
leukocyte infiltration 
DC infiltration 
Mild (n = 16) 4.5 ± 3.8 
Moderate (n = 7) 7.4 ± 5.5 
Marked (n = 11) 11.1 ± 6.9 
3. II. Tumour Necrosis 
The difference in the degree of necrosis between the control and the test 
groups was significant. Marked necrosis was detected in 65% of the treated mice 
compared to 17.5% of controls. Necrosis in the control group was mild in 53.% of 
mice compared to 17.5% of the treated group. The percentage of mice which had 
moderate necrosis in test and control groups was 17.5% and 29.5% respectively 
(Table 1, page 81; Figure 5 a,b,c & 10 page 95,96,97 & 102).The difference 
between both groups was significant (X 2 = 6.07 and P < 0.05; chi sq.). 
Mice in test and control groups were divided into three groups according to the 
degree of necrosis: mild, moderate and marked, the mean of DC infiltration in the 
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three groups was 4.1 ± 3.8, 7.5 ± 7.8 and 9.8 ± 5.4 respectively, the difference of DC 
infiltration between three groups was significant (P < 0.05; anova: single factor). 
Degree of tumour 
necrosis 
DC infiltration 
Mild (n = 12) 4.1 ± 3.8 
Moderate (n = 8) 7.5 ± 7.8 
Marked (n = 14) 9.8± 5.4 
After necrosis of the tumour tissues, sloughing of the necrotic tissue was 
followed by re-epithelization. This phenomenon was noticed in some of the mice in 
the test group but not in the control group ( Figure 6, page 98). 
3. 12. Mouse Weight 
The mice in both groups were weighed before giving the vaccine and after 
three weeks from first vaccination to assess the difference in the weight between 
both groups during this period of time ( Table 5, 6, page 85, 86). The difference was 
not significant between both groups (P > 0.05) indicating that the vaccine did not 
have an effect on mouse weight within this period. The mean weight before and after 
vaccination in the test group was 21.8 ± 2.6 g and 21.5 ± 3.3 g respectively (P> 
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0.05; t-test), and in the control group 22.7 ± 4.3 g before and 22.3 ± 3.9 g after 
vaccination (P > 0.05; t-test). 
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Degree 
Infiltration Necrosis 
Test Control Test Control 
Mild 4 (23.5%) 12 (70.5%) 3 (17.5%) 9 (53%) 
Moderate 4 (23.5%) 3 (17.5%) 3 (17.5%) 5 (29.5%) 
Marked 9(53%) 2(12%) 11(65%) 3(17.5%) 
Total 17 17 17 17 
Table 1: Number of mice with mild, moderate and marked degree of non-
DC leukocytes infiltration and tumour necrosis in test (n = 17) and control 
(n = 17) groups. 
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Mouse Number Tumour 
Diameter before 
Vaccination (mm) 
Tumour 
Diameter after 
Vaccination (mm) 
Difference in 
Tumour 
Diameter (mm) 
% Difference in 
Tumour 
Diameter 
16 10 -6 -37 
2 11 16 +5 45 
3 21 23 +2 9 
4 12 13 +1 8 
5 12 14 +2 16 
6 11 18 +7 63 
7 18 17 -1 -5 
8 12 18 +6 50 
9 16 14 -2 -12 
10 15 17 +2 13 
11 10 20 +10 100 
12 21 35 +14 66 
13 12 10 -2 -16 
14 10 7 -3 -30 
15 11 14 +3 27 
16 10 16 +4 40 
17 7 14 +7 100 
Mean ± sd 13.2± 3.9 16.2 ± 6.2 2.9 ± 5.0 25.97 ± 41.2 
Table 2: Difference in tumour size three weeks following vaccination of the test group. 
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Mouse Number Tumour 
Diameter before 
Vaccination (mm) 
Tumour 
Diameter after 
Vaccination (mm) 
Difference in 
Tumour 
Diameter (mm) 
% Difference in 
Tumour 
Diameter 
1 22 16 -6 -37 
2 17 17 0 0 
3 15 19 +4 26 
4 12 22 +10 83 
5 18 19 +1 4 
6 19 17 -2 -10 
7 21 31 +10 47 
8 21 24 +3 14 
9 20 13 -7 -35 
10 14 21 +7 50 
11 16 16 0 0 
12 12 16 i4 33 
13 20 29 +9 45 
14 9 9 0 0 
15 7 9 +2 28 
16 16 18 +2 12 
17 6 11 +5 83 
Mean ± sd 15.6± 5.0 18.0± 6.1 2.5 ± 4.9 20.2± 34.6 
Table 3: Difference in tumour size three weeks following vaccination of the control 
group. 
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Mouse 
Number 
First Dose 
x 10 5 
Second Dose 
x 10 5 
Third Dose 
x 10 5 
Average Doses 
1 2.7 2.9 1.9 3.0 
2 3.8 2.5 2.7 2.53 
3 1.5 1.7 1.4 1.53 
4 2.0 2.7 3.7 2.63 
5 1.9 2.2 3.2 2.43 
6 2.1 2.7 1.5 2.10 
7 2.5 1.8 2.5 2.26 
8 2.9 2.5 3.1 2.83 
9 2.3 2.6 2.3 2.40 
10 1.4 1.9 1.3 2.53 
11 2.1 1.8 3.5 2.46 
12 2.4 1.9 2.7 2.33 
13 4.1 3.9 2.9 2.65 
14 2.3 2.1 3.7 2.70 
15 1.6 2.2 1.7 1.83 
16 2.9 2.6 2.9 2.80 
17 3.7 3.2 3.8 3.56 
Mean tsd 2.5 ± 0.8 2.4 ± 0.6 2.6 ± 0.8 2.5 ± 0.5 
Table 4: Number of viable cells in the three vaccine doses. 
Tumour cells were irradiated and the viability of the cells was assessed using eosin-y dye 
exclusion. The number of viable cells was calculated according to the formula: 
N x 2x(25/Y)x10 
where N = Number of the viable cells counted, Y = Number of squares counted 
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Mouse Number Weight before 
Vaccination (g) 
Weight after 
Vaccination (g) 
Difference in 
Weight (g) 
% Difference in 
Mouse Weight 
1 29 30 1 3 
2 20 18 -2 -10 
3 24 26 2 8 
4 20 19 -1 -5 
5 19 20 1 5 
6 25 26 1 4 
7 22 20 -2 -9 
8 20 21 1 5 
9 21 22 1 5 
10 24 23 -1 -4 
11 24 22 -2 -8 
12 22 21 1 5 
13 21 22 1 5 
14 20 18 -2 -10 
15 22 21 -1 -5 
16 19 17 -2 -10 
17 19 19 0 0 
Mean ±sd 21.8 ± 2.6 21.5 ± 3.3 -0.2 ± 1.4 -1.2 ± 6.6 
Table 5: Difference in mouse weight three weeks following vaccination of the test 
group. 
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Mouse Number Weight before 
Vaccination (g) 
Weight after 
Vaccination (g) 
Difference in 
Weight (g) 
% Difference in 
Mouse Weight 
1 30 28 -2 -7 
2 28 27 -1 -4 
3 34 32 -2 -6 
4 26 26 0 0 
5 22 23 1 5 
6 22 20 -2 -9 
7 20 21 1 5 
8 19 17 -2 -10 
9 20 21 1 5 
10 21 21 0 0 
11 23 21 -2 -9 
12 19 19 0 0 
13 21 22 1 5 
14 18 18 0 0 
15 24 22 -8 
16 19 20 1 5 
17 21 22 1 5 
Mean ± sd 22.7 ± 4.3 22.3 ± 3.9 -0.4 ± 1.3 -1.3 ± 5.8 
Table 6: Difference in mouse weight three weeks following vaccination of the control 
group. 
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Mouse 
No 
Field 
1 
Field 
2 
Field 
3 
Field 
4 
Field 
5 
Field 
6 
Field 
7 
Field 
8 
Field 
9 
Field 
10 
Mean 
1 4 7 23 6 6 3 1 4 2 1 5.7 
2 0 0 0 0 0 3 2 0 0 1 0.6 
3 0 1 6 1 1 6 14 16 0 1 4.6 
4 3 , 2 7 8 9 6 2 6 8 7 5.8 
5 7 4 7 4 5 1 3 9 6 13 5.9 
6 6 12 3 8 0 13 4 0 0 3 4.9 
7 2 2 8 2 2 3 3 , 0 5 12 3.9 
8 0 0 0 1 0 1 0 0 0 1 0.3 
9 4 5 11 3 2 15 17 9 12 5 8.3 
10 1 0 0 0 0 4 7 3 3 2 2 
11 7 8 7 10 9 17 	• 8 6 11 2 8.5 
12 4 11 1 5 6 11 28 12 5 4 8.7 
13 0 1 0 0 0 2 0 3 5 1 1.2 
14 1 1 2 3 1 1 0 0 1 2 1.2 
15 0 1 1 0 1 4 0 3 1 0 1.1 
16 1 	_4 2 1 3 2 , 1 0 2 0 1.6 
17 2 1 1 5 6 4 4 0 2 3 2.8 
Table 7: Number of DC and the mean in 10 HPF (magnification x200) of 
each mouse in the control group. The mean ± sd of DC for the control 
group was 3.9 ± 2.9. 
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Mouse 
No 
Field 
1 
Field 
2 
Field 
3 
Field 
4 
Field 
5 
Field 
6 
Field 
7 
Field 
8 
Field 
9 
Field 
10 
Mean 
1 11 0 13 32 12 24 14 15 8 2 13.1 
2 0 5 3 2 1 16 11 3 9 6 5.6 
3 1 9 17 16 21 9 16 10 12 7 11.8 
4 0 3 2 , 6 0 0 1 2 1 3 1.8 
5 18 19 4 22 9 24 15 28 16 31 18.6 
6 2 1 5 0 1 0 7 5 8 2 3.1 
7 5 14 8 19 20 7 16 4 •1 28 12.2 
8 1 2 5 7 4 0 15 3 0 8 4.5 
9 5 12 1 5 17 14 11 7 4 12 8.8 
10 25 24 29 14 26 , 24 11 26 7 9 19.5 
11 14 23 16 13 10 14 25 12 6 11 14.4 
12 11 9 19 17 2 13 4 20 17 5 11.7 
13 4 12 16 18 20 18 0 15 14 , 9 12.6 
14 0 0 1 2 2 9 0 2 5 0 2.1 
15 22 34 12 37 31 19 17 19 21 32 24.4 
16 , 26 13 2 6 7 22 8 7 1 4 9.6 
17 20 11 0 3 1 4 3 0 5 3 5 
Table 8: Number of DC and the mean in 10 HPF (magnification x200) of 
each mouse in the test group. The mean ± sd of DC for the test group was 
10.5 ± 6.5. 
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Figure 1 
Mice treated with benzo-a-pyrene twice a week for twenty-four 
consecutive weeks which developed a single skin tumours. 
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■c
) 
C
 
consecutive weeks which developed multiple skin tumours . 
Mice treated with benzo-a-pyrene twice a week for twenty-four 
(a) 
Before 
Vaccination 
(b) 
After 
Vaccination 
Figure 3 (a & b): Difference in tumour size three weeks following 
vaccination. 
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Figure 4 a: Degree of tumour infiltration by leukocytes (mild). 
= Tumour infiltrating leukocytes 
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Figure 4 b: Degree of tumour infiltration by leukocytes (moderate). 
—■ = Tumour infiltrating leukocytes 
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Figure 4 c: Degree of tumour infiltration by leukocytes (marked). 
= Tumour infiltrating leukocytes 
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Figure 5 a: Degree of tumour necrosis (mild). 
= Necrotic tumour cells 
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Figure 5 b: Degree of tumour necrosis (moderate). 
--■ = Necrotic tumour cells 
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Figure 5 c: Degree of tumour necrosis (marked). 
--. = Necrotic tumour cells 
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Figure 6: Tumour sloughing and re-epithelization. 
Tumour necrosis and sloughing followed by re-epithelization was noticed 
in some mice in the test group. 
4. = Tumour sloughing 
—■ = Re-epithelization 
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Figure 7: Dendritic cell infiltration of tumours. 
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Figure 8: Tumour infiltrating Dendritic cells are round with  loss of 
dendrites. 
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Figure 9: Degree of tumour infiltration by leukocytes was categorised as 
mild, moderate and marked. Test and control groups were divided into 
three groups according to the degree of leukocyte infiltration. The results 
shown are the percentage of mice in each group with comparison between 
test (n = 17) and control (n = 17) groups. 
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Figure 10: Degree of tumour necrosis was categorised as mild, moderate 
and marked. Test and control groups were divided into three groups 
according to the degree of tumour necrosis. The results shown are the 
percentage of mice in each group with comparison between test (n = 17) 
and control (n = 17) groups. 
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Figure 11: Mechanical and enzymatic disaggregation of tumour cells 
(mean ± sd). 
Mean percentage of viable cells for mechanical disaggregation (48.6 ± 
10.6) and for enzymatic disaggregation (80.7 ± 10.1). The difference 
between the means was significant (P < 0.05, student's two-tailed unpaired 
t-test, n = 10) 
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Figure 12: Viability of tumour cells before and after washing (mean ± 
sd). 
Mean percentage of viable cells before washing (80.7 ± 10.1) and after 
washing (78.2 ± 7.)3. The difference between the means was not 
significant (P > 0.05, student's two-tailed unpaired t-test, n = 10). 
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Figure 13: Viability of tumour cells before and after radiation (mean 
± sd). 
Mean percentage of viable cells before radiation (67.4 ± 6.9) and after 
radiation (61.6 ± 3.8). The difference between the means was not 
significant (P> 0.05, student's two-tailed unpaired t-test, n = 24). 
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CHAPTER 4 
DISCUSSION 
The effect of autologous tumour cells in inducing an immune response 
against tumour cells has been reported in many studies (Currie et al 1971; Scharfe 
et al 1986; Slingluff et al 1992; Chang et al 1997; Berd et al 1997; Mackenson et 
al 1997). These observations suggest that TSA are not fully exposed to the 
immune system in the tumour bearing host, so that introducing tumour cells which 
carry effective TSA could allow presentation of TSA to the immune system and 
the development of a host anti-tumour response. 
The effect of active specific immunotherapy in this study was evaluated by 
the degree of tumour infiltration by DC and other immune cells, increased 
inflammatory infiltration being taken as an indication of the degree of immune 
response against tumour cells. This assumption is supported by many studies 
which have shown that tumours which undergo spontaneous regression and those 
tumours with a better prognosis are infiltrated by DC, T-lymphocytes and other 
immune cells (Black et al 1953, 1958; Tsakraklides et al 1974; Bulkley 1975; 
Morton et al 1992; Si et al 1996; Berd et al 1997), whilst in advanced tumours 
poor infiltration of tumour by immune cells indicates failure of the immune 
system (Hakanson et al 1997). 
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The effect of tumour vaccine in this study was evaluated by comparing DC 
infiltration of tumour tissues in test and control groups. The DC average per 10 
HPF (magnification x200) ranged from 0.3 to 24.4 with the mean of 10.5 ± 6.5 in 
test group and 3.9 ± 2.9 in the control group, the difference in DC infiltration 
between the two groups being significant (P <0.05), indicating effectiveness of 
vaccination in inducing or enhancing immune responsiveness to the tumour 
according to this criterion. 
In this study the difference in tumour infiltration by non-DC immune cells 
between the vaccinated and non-vaccinated groups was significant. In 70% of the 
control group infiltration was mild compared to 23.5% in the test group. Fifty 
three percent of the mice in the test group had marked infiltration of their tumour 
compared to 12% of the control group. In both groups the percentage of mice 
having moderate infiltration was low (23.5% of the mice in test group and 18% in 
the control group). The difference between the two groups was significant (P < 
0.05). Furthermore, there was correlation between tumour infiltration by non-DC 
leukocytes and tumour infiltration by DC. Tumours with marked infiltration by 
non-DC leukocytes had the highest DC infiltration (mean 11.1 ± 7.0), whereas 
tumours with moderate and mild infiltration by non-DC leukocytes had mean DC 
infiltration of 7.4 ± 5.5 and 4.5 ± 3.7 respectively. The difference between the 
three groups was significant (P < 0.05).This experiment also compared the degree 
of tumour necrosis between test and control groups. Marked necrosis was 
detected in 65% of the treated mice compared to 18% of the control. On the 
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other hand the degree of necrosis in the control group was mild in 53% of the 
mice while only 17.5% of the test group had mild necrosis. The number of mice 
which had moderate necrosis was 29% in the control group and 17.5% in the test 
group. The difference between the control and the treated groups was significant 
(P< 0.05). The area of necrosis was usually surrounded by infiltrating immune 
cells (lymphocytes, macrophages and neutrophils). There was correlation between 
tumour necrosis and tumour infiltration by DC. Tumours with marked necrosis 
had the highest DC infiltration (mean 9.8 ± 5.4), whilst tumours with moderate 
and mild necrosis had mean DC infiltration of 7.5 ± 7.8 and 4.1 ± 3.8 
respectively. The difference between the three groups was significant (P < 0.05). 
Dendritic cells are highly efficient antigen presenting cells able to process 
and present antigen to T-cells and to initiate cellular immune response (Stingle et 
at 1978; Sertl et at 1986; Hopkins et at 1989; Grabbe et at 1991, 1992; Van-
Schooten et at 1997). Since presentation of antigen to the immune system by DC 
is critical to elicitation of strong immune responses this study evaluated the 
effectiveness of tumour vaccine on promoting DC infiltration of tumour tissues. 
Some carcinogens promote tumour development by inhibiting the function or the 
number of DC, with cessation of carcinogen administration followed by reversible 
changes of DC number and function and subsequent regression of tumours 
(Muller et at 1985; Zeid et al 1995). 
Many studies have reported evidence of correlation between the presence 
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of DC in tumours and good prognosis (Furukwa et at 1985; Nomori et al 1986; 
Schroder eta! 1988; Ambe et al 1989; Tsujitani et al 1987,1990). The presence of 
these cells near the tumour is associated with reduced development of metastasis, 
whilst the absence of these cells is associated with widespread dissemination of 
tumour cells. Furthermore DC density correlate with tumour histological stage and 
vascular invasion (Matsuda et al 1990; Maehara et al 1997). Antigen presentation 
by DC therefore appears to be a critical component of development of adoptive 
anti-tumour immunity, this immunity being antigen specific and capable of 
rejecting tumour cells carrying that antigen (Celluzzi et al 1996). 
In animal models, regression of metastatic nodules has been observed in 
tumour-bearing animals treated with DC alone or DC pulsed with tumour extract. 
DC were able to elicit tumour specific CTL responses in tumour-bearing animals 
(Yang et al 1997b). DC Sensitized to tumour peptide were able to suppress 
growth of weakly immunogenic tumours, this effect of DC mediated through CTL 
(Zitvogel et al 1996a). In human trials, vaccine consisting of Granulocyte 
Macrophage-Colony Stimulating Factor (GMCSF) and irradiated autologous 
melanoma cells led to increased numbers of DC at the vaccination site which was 
followed by development of Delayed-Type Hypersensitivity (DTH) to autologous 
tumour cells (Ellem eta! 1997). 
Infiltration of tumour tissue by immune cells other than DC, especially T-
cells has also been claimed to be an indication of an effective immune response 
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against tumour cells. Patients may have better or worse prognosis depending on 
the degree of tumour infiltration by immune cells, high levels of infiltration being 
associated with better prognosis, and low or no infiltration with a poor prognosis 
(Hamlin 1968; Svenning et at 1979; Eccles et al 1974, Zeid et al 1993; Berd et al 
1997). 
Recognition of TSA by DC should be followed by presentation of TSA to 
T-cells which initiate an immune response against tumour cells carrying this 
antigen, mediated mainly by CTL (Grabbe et at 1991; Bakker et at 1995; 
Zitvogel et at 1996; Ellem et at 1997; Van-Schooten et at 1997; Mayordomo et at 
1997). Infiltration of tumour tissues by DC therefore may indicate host immunity 
against tumour cells (Matsuda et al 1990; Si et at 1996; Maehara et at 1997). DC 
infiltration of tumour thus may serve as an indicator of tumour cell ability to 
evoke an immune response, i.e. DC could be used as an indicator for the possible 
presence of TSA which are capable of inducing effective immunity if TSA were 
to be presented adequately in the presence of a competent immune system. 
Infiltration of tumour by DC might be used to identify those tumours which are 
able to evoke an immune response without necessarily having to identify the 
structure of TSA. Tobacco derived BP-induced tumour has been reported to be 
highly infiltrated by DC (Ruby et al 1989). Regression of tumour induced by 
tobacco smoke condensate (TSC) and Dimethylbenz-a-anthracene (DMBA) is 
associated with increased density of DC in these tumours (Muller et at 1985; 
Zeid et al 1995). These observations were taken into consideration in this study 
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in choosing to apply tumour vaccine to BP-induced tumours, since they also tend 
to be infiltrated by high numbers of DC which might reflect the immunogenicity 
of these tumours, and provide an opportunity to correlate host responsiveness to 
extent of DC-infiltration of tumour used for vaccine production. However the 
ability of some tumours to attract higher numbers of DC than others may partly 
be linked to the ability of some tumour cells to produce tumour derived cytokines, 
which attract DC to the lesion (Halliday et al 1992). Some tumours with low DC 
infiltration may express antigens or produce other factors which inhibit DC 
accumulation and subsequently inhibit tumour immunity (Qin et al 1997). 
Some immunogenic tumours fail to induce an effective immune response. 
This may be due to inadequate exposure of TSA to the DC or due to a suppressed 
immune system, which may recognize the antigen but be unable to produce an 
effective immune response against that antigen. Activation of T-cells and 
generation of CTL not only requires processing of TSA by DC in the presence of 
MHC antigen but also delivery of a costimulatory signal, this signal delivered to 
CTL through the B7 surface molecule present on the surface of DC. Blocking of 
this signal or failure of DC to express this molecule leads to inhibition of immune 
responses (Linsley et al 1997; Boussiotis et al 1997; Chaux eta! 1997; Brossart et 
al 1997). 
Some studies have reported that DC infiltration of skin tumours is 
unlikely to reflect the immunogenicity of tumour cells or host immunocompetence 
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since DC infiltration of immunogenic and non-immunogenic tumours was the 
same whether these tumours were transplanted into immunocompetent or athymic 
mice (Bergfelt et al 1988; Halliday et al 1991). However several recent studies 
have shown that DC play an important role in immune responses to tumour. 
Tumour regression is associated with increased numbers of DC (Muller et al 
1985; Zeid et al 1995; Si et al 1996), increased numbers of DC are accompanied 
by immunological and clinical responses, and DC infiltration is decreased in 
relation to extent of lymph node metastasis (Maehara et al 1997). Furthermore the 
efficacy of DC as a vaccine and the ability of DC to elicit tumour specific CTL 
have been shown in many recent studies (Mayordomo et al 1997; Ellem et al 
1997; Bronte et al 1997; Nair eta! 1997). 
Increased immune cell infiltration of tumours in the test group compared 
to the control group was taken in this study to reflect enhancement of the immune 
system by the vaccine. Infiltrating immune cells consisted of lymphocytes, 
macrophages and neutrophils. However lymphocytes comprised the majority of 
infiltrating cells. Infiltration by other immune cells such as macrophages and NK 
cells are also considered part of the immune defence against cancer (Marina et al 
1981; Trinchieri 1989, Galligioni et al 1993; Yang et al 1997b; Ellem eta! 1997). 
The presence of necrosis within tumour tissues might attract high number of 
macrophages and neutrophils to the tumour site but this does not exclude the role 
of these inflammatory cells in an immune response. Some studies showed that 
healthy tumours and necrotic tumours are infiltrated to the same degree by 
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macrophages (Evans 1972). 
In this study there was no correlation found between the degree of tumour 
necrosis and the difference of tumour size before and after vaccination. Some 
mice with marked necrosis had enlarged tumours whilst others with the same 
degree of necrosis had stable tumour size. Despite the significant difference 
between the control and the treated mice in the degree of necrosis, no significant 
difference could be detected in the size of the tumour between both groups. This 
observation may be due to the fact that the mice were killed three weeks after the 
first vaccination and this period might not be long enough for clinical regression. 
Different amounts of tumour volume may also be accounted for early in an anti-
tumour immune response by oedema and inflammatory infiltration. 
There was no correlation between the degree of DC infiltration of tumours 
in treated mice and the dose of the vaccine. This indicates that tumour cell dose 
was effective within the range of 1.53 - 3. 63 X 10 5 , however no dose-response 
conclusions can be drawn. Further experiments with tumour dose beyond these 
ranges would be required. These results indicate that this vaccine and method of 
vaccination does induce an immune response to this relatively high DC containing 
tumour in mice. 
The injection site of vaccination was chosen to be away from the tumour 
site to prevent a direct effect of the vaccine on the tumour tissues. This approach 
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assured that the effect of the vaccine on the tumour tissues was due to a systemic 
response to the vaccine, and not a local inflammatory response. 
Administration of irradiated tumour vaccine has been shown to lead to 
lymphocytosis in regional lymph nodes and development of inflammatory 
response in metastatic tumours (Sensi et al 1997). Recent advances in 
understanding the requirement for T-cell activation indicates that effective antigen 
presentation is a key requirement for production of tumour specific CTL. TSA 
should be appropriately processed and displayed in association with MHC 
antigen (Mackenson et al 1997; Guo et al 1997; Yang eta! 1997b). Furthermore a 
costimulatory signal should be delivered to T-cells though through a molecule on 
the DC surface to induce an effective immune response (Wang et al 1997; Yang et 
al 1997b; Gerstmayer et al 1997). 
In this experiment part of the tumour was excised surgically to prepare the 
vaccine. Surgical debulking of tumours may help in producing an immune 
response against unresected parts of the tumour. The immune response against 
tumour tissues may be present in the host but are "swamped" by the large amount 
of antigen present or inhibited by large amounts of immuno-suppressive factors 
released from the tumour. Partial resection of the tumour may reduce these 
factors and allow an effective immune response to the residual lesion. In this 
experiment both groups, control and test, underwent partial resection of their 
tumours to exclude the possibility that the immune system was enhanced by 
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reducing tumour mass rather than by the effect of the vaccine. 
In the present work animals were exposed to TSA by injecting them with 
whole irradiated tumour cells. Some trials have used cell fragments as a vaccine 
presuming the presence of TSA on the cell fragments (Neildhart et at 1988; 
Ravindranath et al 1997). Synthetic antigen has also been used to induce 
immunity against cancer cells carrying that antigen (Blume et al 1994; Zhai et at 
1997). Identification of TSA is a difficult task. TSA have been identified in some 
histological types of tumours but not others. However identification of TSA does 
not necessarily mean that the identified antigen is responsible for specific tumour 
immunity, since tumour cells may carry many tumour antigens, some 
immunogenic and some not immunogenic (Jager et at 1996). Furthermore, more 
than one antigen may be responsible for specific immune responses against 
tumour cells and it is difficult to identify the structures of all tumour antigens. 
Taking into account these considerations, this study was designed to use 
irradiated whole tumour cells as active specific immunotherapy. Whole tumour 
cells are relatively easy to obtain from tumour tissues, and these cells carry TSA 
whether they are immunogenic or non-immunogenic, so it is not necessary to 
identify TSA or to identify which TSA are immunogenic and which are not in 
order to study the immunological response.. 
In this study autologous tumour vaccine was prepared from squamous cell 
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carcinomas induced in mice by BP. Autologous cells were used to prepare the 
vaccine rather than the allogeneic cells from mice of the same strain, as each 
induced tumour may develop specific TSA different from TSA carried by other 
tumours of the same histological type and same method of tumour induction 
(Slingluff 1996). These antigens can provoke an immune response specifically 
against tumour cells that carry only that antigen (Chang et at 1997). Studies which 
supported the presence of a unique antigen for each tumour despite histological 
similarity depended on the observation that cross reactivity between allogeneic 
tumour cells and immune cells did not occur for some tumours. In addition, 
diversity of tumour antigen is reported in tumours induced by the same carcinogen 
in different hosts (Klein et al 1960; Globerson et al 1964; Schirrmacher et al 
1979; Cortes et al 1984). Furthermore recent studies have shown that cytotoxic 
activity of stimulated PBL against autologous tumour cells are significantly higher 
than that against allogeneic tumour cells (Strohlein et al 1997). The presence of 
common antigens among tumours of the same histological type has been reported 
in some tumours however (Morton et al 1968; Cornain et al 1975; Wagner et al 
1997). Many studies reported promising results using allogeneic tumour cells as 
tumour immunotherapy, but this cannot be generalized to all tumour types 
(Slingluff eta! 1992; Morton et al 1992 ; Yang et al 1997a). Allogeneic tumour 
cells may induce immunity by involving antigens other than TSA on allogeneic 
tumour cells. In addition identical MHC on tumour cells may be required for an 
effective immune reaction (Yang eta! 1997b). 
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Tumour cells were irradiated before vaccination to stop cell proliferation 
whilst maintaining the antigenicity of tumour cells. The viability of tumour cells 
was determined before and after irradiation. The mean percentage of viable cells 
before irradiation was 67.4% and after irradiation was 61.6%. It has been reported 
that viability of 33% or more of tumour cells is effective as an immunogenic 
vaccine (Ahlert et al 1997). The difference between the two viability readings in 
the present study was not significant (P > 0.05). This indicates that irradiation did 
not have significant effect on the viability of tumour cells. 
X-ray dosage was adequate to prevent tumour-cell division since no 
evidence of tumour cell implantation was detected within three weeks after the 
first vaccination. However this period may not be long enough for clinical 
evidence of tumour implantation at the site of injection. To exclude the possibility 
of tumour implantation, tumour cells were incubated for one week in tissue 
culture medium in a CO2 incubator after irradiation, whilst non-irradiated tumour 
cells were incubated as a control for the same period. No significant cell 
proliferation was detected in flasks containing irradiated cells compared to 
tumour cell proliferation in flasks containing non-irradiated cells. 
Several studies have used cell extract as a vaccine (Neildhart et al 1988; 
Mitchell et al 1988; Slingluff et al 1992; Ravindranath et al 1997). Procedures for 
preparing cell extract may lead to modification or destruction of tumour antigen 
which in turn might be responsible for apparent immunity against tumour cells. In 
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addition recognition of TSA by the immune system requires other cell membrane 
structures on the tumour cell particularly MHC antigen (Yang et al 1997b; Chang 
et al 1997). By using irradiated tumour cells the likelood of TSA alteration or 
MHC antigen loss was reduced and was more likely to produce a true tumour 
specific response. 
Cryopreservation caused a decrease in cell viability of 10-30%. This drop 
may have been due to the condition of tumour cells before freezing, since some 
cells could have been exhausted during disaggregation despite the fact that they 
appeared viable before freezing. However other factors may affect the viability, 
such as the technique of thawing tumour cells, the temperature at which the 
tumour cells are stored and the method of cryopreservation. 
Enzymes used for tissue disaggregation may affect the antigens carried by 
the cells. Some enzymes may directly affect surface antigens leading to decreases 
in immunogenicity, whilst other enzymes may enhance immunogenicity, for 
example by removing blocking material or antibodies (Pincus 1981; Seigler et al 
1979). In this experiment trypsin was used for disaggregation of tumour cells. The 
effect of this enzyme in modifying TSA could not be excluded since the 
structure of the TSA responsible for specific tumour immunity in this experiment 
has not been identified. 
In conclusion the data presented in this study has demonstrated that active 
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specific immunotherapy is able to induce immunity against BP induced squamous 
cell carcinomas in mice. This tumour type has a relatively high number of DC. 
Taken together with other studies of tumour types with varying characteristic 
levels of DC infiltration used to produce vaccines, this study offers supporting 
evidence that tumours with higher numbers of DC tend to be more responsive to 
vaccine-induced immunity than tumours with lower numbers of DC. It is possible 
that DC infiltration could be used as a marker of tumours for which vaccine 
production is worthwhile. Furthermore, this study has examined DC infiltration as 
a marker of tumour response to vaccination and provides evidence that DC 
infiltration does reflect immune response to vaccination, correlating with 
appearance of tumour necrosis and appearance of non-DC leukocytes. 
Further investigation to additionally examine these conclusions could 
include an attempt to correlate the effectiveness of vaccination with DC 
infiltration variation within individual tumour types. Additional studies need to be 
carried out to evaluate the effect of tumour vaccine produced from different 
histological types of tumours which are characteristically infiltrated by high or 
low numbers of DC. 
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